Yi-Xin Zeng
    Title Academician of the Chinese Academy of Sciences, Professor and Former President

    Dr. Yi-Xin Zeng had been the President of Sun Yat-sen University Cancer Center since 1997 till 2013. He had served as the Director of State Key Laboratory of Oncology in South China since 2004. Now he is a professor and president of Peking Union Medical College. Dr. Zeng obtained his PhD and MD at Sun Yat-sen University of Medical Sciences in 1990. He was elected as member of the Chinese Academy of Science in 2005. He received his post-doc training on molecular mechanisms of cancer pathogenesis in Tokyo Metropolitan Institute of Gerontology, Tokyo University and University of Pennsylvania from 1992 to 1997. He was appointed as a professor of Sun Yat-sen University of Medical Sciences and vice president of Sun Yat-sen University Cancer Center after he returned to China in 1997. He was elected as Outstanding Young Teacher by Ministry of Education in 2002, Outstanding Young Expert by Ministry of Health in 2006.

    His research is devoted to the pathogenesis of cancer and cancer biotherapy, with a focus on nasopharyngeal carcinoma (NPC) and Epstein-Barr virus (EBV), on which he has published over 300 papers in international famous journals including Nature, Nature Genetic and Cancer Research. He has been honored with many awards for his research, including Second Class Award for Natural Science Achievements (National Office for Science and Technology Awards, 2005), He-Liang-He-Li Award for Science and Technology Advancement (2007), Award for Outstanding Science and Technology Achievements in Guangdong Province (the People's Government of Guangdong Province, 2011).

    Currently Dr. Zeng is leading the 863 program (National High Technology Research and Development Program of China) “Molecular Classification and Individualized Therapy for Major Diseases” and 973 program (National Basic Research Program of China) “Research on Mechanisms and Intervene of Oncogenic Virus”.

    He served as the president of International Association of EB Virus and Related Diseases from 2006 to 2008. He is the chief editor of national postgraduate textbook Oncology designed by the Minister of Health, the Editor-in-chief of the Chinese Journal of Cancer and Vice Editor-in-chief of medicine undergraduate textbook Clinical Oncology. He has also acted as the vice president of China Anti-Cancer Association since 2007.

    Research Interest(s)

    1. Identification and functional characterization of nasopharyngeal (NPC) susceptibility genes

    2. Identification and functional characterization of NPC associated Epstein-Barr Virus (EBV) subtypes

    3. Gene, EBV and environment interactions in the pathogenesis of NPC

    4. Cancer biotherapy and intervene of EBV in the early stage of NPC pathogenesis

    For information on Professor Zeng's laboratory, click here and select: Identify and Map the Susceptibility Genes Contributing to NPC.

    Howard Hughes Medical Institute, University of Pennsylvania School of Medicine, Research Associate, 1994 -1997

    Institute of Medical Science, Tokyo University and Tokyo Metropolitan Institute of Gerontology, Posdoc Fellow, 1992 -1994

    Sun Yat-sen University of Medical Sciences, Guangdong Province, China. M.D., Ph.D., 1990.

    HengYang Medical College, Hunan Province, China. B.S. in Medicine, 1985.


    1. Liu P, Fang X, Feng Z, Guo YM, Peng RJ, Liu T, Huang Z, Feng Y, Sun X, Xiong Z, Guo X, Pang SS, Wang B, Lv X, Feng FT, Li DJ, Chen LZ, Feng QS, Huang WL, ZengMS, Bei JX, Zhang Y, Zeng YX. Direct sequencing and characterization of aclinical isolate of Epstein-Barr virus from nasopharyngeal carcinoma tissue byusing next-generation sequencing technology. J Virol. 2011, 85(21):11291-9.

    2. Bei JX, Li Y, Jia WH, Feng BJ, Zhou GQ, Chen LZ, Feng QS, Low HQ, Zhang H, He F, Tai ES, Kang TB, Liu ET, Liu JJ and Zeng YX. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010, 42(7):599-603.

    3. Liang Y, Zhong ZD, Huang Y, Deng W, Cao J, Tsao G, Liu Q, Pei DQ, Kan TB and Zeng YX. Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. J Biol Chem. 2010, 285:4931-40.

    4. Feng BJ, Huang W, Shugart YY, Lee MK, Zhang F, Xia JC, Wang HY, Huang TB, Jian SW, Huang P, Feng QS, Huang LX, Yu XJ, Li D, Chen LZ, Jia WH, Fang Y, Huang HM, Zhu JL, Liu XM, Zhao Y, Liu WQ, Deng MQ, Hu WH, Wu SX, Mo HY, Hong MF, King MC, Chen Z, Zeng YX. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet. 2002 ,31(4):395-9.

    5. Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Zhang H, Wu GS, Licht JD, Weber BL, El-Deiry WS. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature. 1997, 11;389(6647):187-90.6. Zeng YX, Somasundaram K, el-Deiry WS. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet. 1997,15(1):78-82.

    Last updated on: 2011

    Zeng Mu-Sheng
    Title Professor and Vice-President

    Prof. Mu-Sheng Zeng is a vice director and professor of Sun Yat-sen University Cancer Center. He gained his Ph.D. degree at Sun Yat-sen University in 1998 and had his Post-doc training in Tennessee State University and New England Medical Center, Tufts University from 1999 to 2003. Prof. Mu-Sheng Zeng moved back to China to start his lab in 2003. In 2010, he supported by The National Science Fund for Distinguished Young Scholars.  In 2014, he was awarded as The Yangtze River Scholar Distinguished Professor from Ministry of Education of China. In 2016, he was awarded as Distinguished Scholar Professor of Guangdong province. In 2021, he was awarded as Young and middle-aged Expert with outstanding contribution to National health. In 2018, he was elected as chairman of the 2022 Nasopharyngeal Carcinoma Gordon Research Conference (The start of the conference was pushed back from 2022 to 2024 due to the COVID-19). In the same year, he was awarded The First Prize of the Guangdong Provincial Natural Science Award. In 2019,  he was awarded The First Prize of Science and Technology Award of China Anti-Cancer Association. In 2022, he was awarded The First Prize of Academy of Higher Education Award for Outstanding Achievements in Scientific Research.

    Research Interest(s) Epstein-Barr virus (EBV) is the first human oncogenic virus discovered, and is closely related to nasopharyngeal carcinoma, some lymphomas and gastric cancer, and is also the cause of infectious mononucleosis in adolescents, which seriously harms people's health, but there are no vaccines and specific antiviral drugs available for more than 50 years. Prof. Zeng made outstanding contributions to the pathogenesis and intervention of EBV, answering an international conundrum: EBV usually infects only lymphocytes, why can it infect nasopharyngeal epithelial cells in South China and some Southeast Asian countries, and how to prevent nasopharyngeal cancer? 1) He established an in vitro model of EBV infection of epithelial cells, found all the receptors for Epstein-Barr virus to enter epithelial cells, and then revealed the new mechanism of Epstein-Barr virus causing nasopharyngeal carcinoma, providing scientific basis for intervention of Epstein-Barr virus infection; 2) He found a new epithelial-immune dual feature cell type in nasopharyngeal carcinoma. Tumor cells with this feature could enhance the depletion of CD8+ T cells and promote the tumor progression of nasopharyngeal carcinoma, laying a theoretical foundation for the study of new immunotherapy schemes for nasopharyngeal carcinoma; 3) He repoted the complete atomic structure of EBV nucleocapsid, providing a key structural basis for the research and development of drugs that block the maturation of viral capsid; 4) He identified the carcinogenic EBV high-risk subtypes, and developed EBV prophylactic self-assembled nanoparticles vaccine platform and EBV therapeutic mRNA vaccine platform.  Now his research team cooperate with biomedical companies to promote the fundamental and translational research on EBV prophylactic and therapeutic vaccines. Leveraging strong cross-company partnerships and expertise, he worked together with company to advance research and bring this groundbreaking vaccine closer to reality, offering new hope to patients battling these challenging diseases. He achieved major theoretical breakthroughs in the field of pathogenesis and prevention of EBV related diseases, providing key basic support for vaccine and drug research and development, and promoting the development of the field.  Professor Zeng won the first prize of the Natural Science Award of the Ministry of Education, the first prize of the Natural Science Award of Guangdong Province and the first prize of the Science and Technology Award of the Chinese Anti-Cancer Association. As a corresponding or co-corresponding author, he published more than 70 papers in Nat Microbiol, Cell Res, ACS Nano, J Clin Invest, Nature Commun, PNAS, J Natl Cancer Inst and other internationally renowned journals. He is consecutively selected by Elsevier highly cited scholars with h-index 57 and a total of 11,934 times cited.

    1988   College Degree in Clinical Medicine

    Jiangxi Medical College in Fuzhou, Jiangxi, China

    1994  M.M. in Oncology

    Sun Yat-Sen University, Guangzhou, China

    1998  Ph.D. in Microbiology

    Sun Yat-Sen University, Guangzhou, China

    1999-2000  Postdoc in Biology

    Tennessee State University, USA

    2000-2003  Postdoc in Radiation Oncology

    New England Medical Center, Tufts University, USA


    1) Cong Sun#, Yin-Feng Kang#, Yuan-Tao Liu, Xiang-Wei Kong , Hui-Qin Xu , Dan Xiong , Chu Xie , Yi-Hao Liu , Sui Peng , Guo-Kai Feng* , Zheng Liu *, Mu-Sheng Zeng*. Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. Signal Transduct Target Ther. 2022 Feb 8;7(1):42.
    2) Yin-Feng Kang#, Cong Sun#, Jing Sun#, Chu Xie, Zhen Zhuang, Hui-Qin Xu, Zheng Liu, Yi-Hao Liu, Sui Peng, Run-Yu Yuan*, Jin-Cun Zhao*, Mu-Sheng Zeng*. Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. Nat Commun. 2022 May 13;13(1):2674.
    3) Yin-Feng Kang#, Cong Sun#, Zhen Zhuang#, Run-Yu Yuan#, Qing-Bing Zheng, Jiang-Ping Li, Ping-Ping Zhou, Xin-Chun Chen, Zhe Liu, Xiao Zhang, Xiao-Hui Yu, Xiang-Wei Kong, Qian-Ying Zhu, Qian Zhong, Miao Xu, Nan-Shan Zhong, Yi-Xin Zeng, Guo-Kai Feng*, Chang-Wen Ke*, Jin-Cun Zhao*, and Mu-Sheng Zeng*. Rapid Development of SARS-CoV 2 Spike Protein Receptor-Binding Domain Self Assembled Nanoparticle Vaccine Candidates. .  ACS Nano 2021, 15, 2738−2752. 
    4) Kang YF, Zhang X, Yu XH, Zheng Q, Liu Z, Li JP, Sun C, Kong XW, Zhu QY, Chen HW, Huang Y, Xu M, Zhong Q, Zeng YX*, Zeng MS*. Immunization with a self-assembled nanoparticle vaccine elicits potent neutralizing antibody responses against EBV infection. Nano Lett.2021 Mar 8;21(6):2476-86.
    5)Zhu QY, Shan S, Yu J, Peng SY, Sun C, Zuo Y, Zhong LY, Yan SM, Zhang X, Yang Z, Peng YJ, Shi X, Cao SM, Wang X*, Zeng MS*, Zhang L*. A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus. Nat Commun. 2021 Nov 16;12(1):6624.
    6)Shanzhao Jin, Ruoyan Li, Ming-Yuan Chen, Chao Yu, Lin-Quan Tang, Yan-Min Liu, Jiang-Ping Li, Yi-Na Liu, Yi-Ling Luo, Yifan Zhao, Yu Zhang, Tian-Liang Xia, Shang-Xin Liu, Qi Liu, Guan-Nan Wang, Rui You , Jing-Yun Peng, Jiang Li, Feng Han, Jianwei Wang, Qiu-Yan Chen, Li Zhang, Hai-Qiang Mai, Benjamin E Gewurz, Bo Zhao, Lawrence S Young, Qian Zhong*, Fan Bai*, Mu-Sheng Zeng*. Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma. Cell Res. 2020 Nov;30(11):950-965.
    7)Li Z, Zhang X, Dong L, Pang J, Xu M, Zhong Q, Zeng MS*, Yu X*. CryoEM structure of the tegumented capsid of Epstein-Barr virus. Cell Res. 2020 Oct;30(10):873-884.
    8)Zhang H, Li Y, Wang HB, Zhang A, Chen ML, Fang ZX, Dong XD, Li SB, Du Y, Xiong D, He JY, Li MZ, Liu YM, Zhou AJ, Zhong Q, Zeng YX, Kieff E, Zhang ZQ, Gewurz BE, Zhao B*, Zeng MS*. Ephrin receptor A2 is an epithelial cell receptor for EBV entry. Nat Microbiol, 2018 Feb;3(2):164-171
    9)Tang LQ, Zhang H, Li Y, Zhang A, Chen ML, Li SB, Mai HQ, Zeng MS*. A Sponsored Supplement to Science:Precision medicine in China,Chapter 2, Precision medicine for nasopharyngeal carcinoma, Science, 2016.12.23, 24~27
    10)Xiong D, Du Y, Wang HB, Zhao B, Zhang H, Li Y, Hu LJ, Cao JY, Zhong Q, Liu WL, Li MZ, Zhu XF, Tsao SW, Hutt-Fletcher LM, Song E, Zeng YX, Kieff E*, Zeng MS*. Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells. PNAS. 2015 Sep 1;112(35):11036-41.
    11)Wang HB, Zhang H, Zhang JP, Li Y, Zhao B, Feng GK, Du Y, Xiong D, Zhong Q, Liu WL, Du H, Li MZ, Huang WL, Tsao SW, Hutt-Fletcher L, Zeng YX, Kieff E, Zeng MS*. Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells. Nat Commun. 2015 Feb 11;6(1):6240.
    12)Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, Kong QL, Xu LH, Zhang X, Liu WL, Li MZ, Zhang L, Kang TB, Fu LW, Huang WL, Xia YF, Tsao SW, Li M, Band V, Band H, Shi QH, Zeng YX, Zeng MS*. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest. 2009 Dec 1;119(12):3626-36.

    Zhu Xiaofeng
    Title Director and Professor

    Zhu Xiaofeng is the deputy director of the Experimental Research Department and a professor in the State Key Laboratory of Oncology in South China. He is also the Director of the Committee of Cancer pharmacology in Guangdong Pharmacological Society, a Standing member of the Committee of Cancer pharmacology in Chinese Pharmacological Society, aStanding member of the Committee of anticancer drug in Chinese association for cancer research, Editorial board member for Chinese Journal of Cancer; Editorial board member for Frontier in Pharmacology and an Advisory board member for Advances in Therapy. His main research interest is Signal transduction in cancer and targeted anticancer drugs.

    He also is at the origin of 8 patents and products such as Shikonin derivatives and their antitumor effect or Houttuyninum compositions and methods for inhibiting the activity of erbB-2 based thereon and was awarded with numerous grants and honours, for example for Targeted therapy for cancer stem cells., 973 program, 4,500,000yuan RMB, from 2012 to 2016.


    Research Interest(s)

    Signal transduction in cancer and targeted anticancer drugs


    Patents and Products
    1) Shikonin derivatives and their antitumor effect. ZL02114973.9
    2) Houttuyninum compositions and methods for inhibiting the activity of erbB-2 based thereon. PCT/US01/43123。
    3) Quinoline derivatives substituted by aliphatic amino groups, the preparation and the pharmaceutical use thereof. ZL200310112457.3;PCT/CN2004/000175.
    4) HER2 tyrosine kinase inhibitors. 200410052496.3
    5) A novel Chalconeomixe and its function. ZL200510101717.6
    6)Preparation and antitumor effect of Hirsutanols A. Patent application number: 200910037541.0
    7) 5-thiazole compounds and their biological function. Patent application number:2010102651155
    8) Anonin injection for cancer therapy transfered to Sanjin Pharmaceutical Company for development.

    For information on Professor Zhu's laboratory, click here and select: Signal transduction and targeted drugs in cancer, cancer stem cells and autophagy in nasopharyngeal carcinoma and ovarian cancer.

    2000,1----2000,9   Visiting scholar, Structure biology and anticancer drug discovery program, Georgetown University Lombardi Cancer Center
    1997,9----2000,12  Ph.D. in Oncology, Cancer center, Sun Yat-sen University of Medical Sciences
    1993,9----1996,7  Master Degree in Oncology, Cancer center, Sun Yat-sen University of Medical Sciences
    1988,9----1993,7   M.D, Clinical medicine, Wannan Medical College


    1. Ting Sun, Xuan Li, Peng Zhang, Wen-Dan Chen, Hai-Liang Zhang, Dan-Dan Li, Rong Deng, Xiao-Jun Qian, Lin Jiao, Jiao Ji, Yuan-Tian Li, Rui-Yan Wu, Yan Yu, Gong-Kan Feng, Xiao-Feng Zhu*. Acetylation of Beclin 1 inhibits autophagosome maturation and promotes tumour growth. Nat Commun. 2015; 6: 7215.

    2. Jing-Hong Chen, Peng Zhang, Wen-Dan Chen, Dan-Dan Li, Rong Deng, Xuan Li, Jiao Ji, Gong-Kan Feng, Yi-Xin Zeng, Jian-Wei Jiang*, Xiao-Feng Zhu*. ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to topotecan in cancer cells. Autophagy, 2015; 11(2): 239-52

    3. Yun-Tian Li, Xiao-Jun Qian, Yan Yu, Zhen-Hua Li, Rui-Yan Wu, Jiao Ji, Lin Jiao, Xuan Li, Peng-Fei Kong, Wen-Dan Chen, Gong-Kan Feng, Rong Deng, Xiao-Feng Zhu*. EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy. Oncotarget. 2015 Apr 29. [Epub ahead of print]

    4. Xiao-jun Qian, Yun-tian Li, Yan Yu, Yang Fen, Rong Deng, Jiao Ji, Lin Jiao, Xuan Li, Rui-Yan Wu, Wen-Dan Chen, Gong-Kan Feng, Xiao-Feng Zhu*. Inhibition of DNA Methyltransferase as a Novel Therapeutic Strategy to Overcome Acquired Resistance to Dual PI3K/mTOR Inhibitors. Oncotarget. 2015; 6(7): 5134-46

    5. Juan Qin, Jiao Ji, Rong Deng, Jun Tang, Fen Yang, Gong-Kan Feng, Wen-Dan Chen, Xiao-Qi Wu, Xiao-Jun Qian, Shao-Hua Chang, Ke Ding, Xiao-Feng Zhu*. DC120, a novel AKT inhibitor, preferentially inhibits nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2 expression. Oncotarget. 2015; 6(9):6944-58

    6. Yang F, Deng R, Qian XJ, Chang SH, Wu XQ, Qin J, Feng GK, Ding K, Zhu XF*. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer. Cell Death Dis. 2014 Mar 13;5:e1114.

    7. He JH, Liao XL, Wang W, Li DD, Chen WD, Deng R, Yang D, Han ZP, Jiang JW, Zhu XF*. Apogossypolone, a small-molecule inhibitor of Bcl-2, induces radiosensitization of nasopharyngeal carcinoma cells by stimulating autophagy. Int J Oncol, 2014:45(3): 1099-108.

    8. Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK, Zhu XF*. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.  PLoS One. 2013;8(3):e59879

    9. Xiao-Yue Zhang, Xiao-Qi Wu, Rong Deng, Ting Sun, Gong-Kan Feng, Xiao-Feng Zhu*. Upregulation of sestrin 2 expression via JNK pathway activation contributes to autophagy induction in cancer cells. Cell Signal. 2013 Jan;25(1):150-8

    10. Rong Deng, Fen Yang, Shao-Hua Chang, Jun Tang, Juan Qin, Gong-Kan Feng, Ke Ding, Xiao-Feng Zhu*. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth. Mol Pharmacol, 2012, 82(2):189-98

    11. Jun Tang, Rong Deng, Rong-Zhen Luo, Guo-Ping Shen, Mo-Yan Cai, Zi-Ming Du, Shang Jiang, Ming-Tian Yang, Jian-Hua Fu, Xiao-Feng Zhu*. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat, 2012, 134(2):549-60

    12. Dan-Dan Li, Ting Sun, Xiao-Qi Wu, Shu-Peng Chen, Rong Deng, Shan Jiang, Gong-Kan Feng, Jin-Xuan Pan, Xiao-shi Zhang, Yi-Xin Zeng, Xiao-Feng Zhu*. The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type p53 but Not Mutant p53 to Topotecan Treatment. PLoS ONE*, 2012, 7(9): e45058. doi:10.1371/journal.pone.0045058

    13. Rong Deng, Jun Tang, Jian-Guo Ma, Shu-Peng Chen, Liang-Ping Xia, Wen-Jun Zhou, Dan-Dan Li, Gong-Kan Feng, Yi-Xin Zeng, Xiao-Feng Zhu*. PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene, 2011, 30: 944-55

    14. Dan-Dan Li, Jin-Feng Guo, Jia-Jia Huang, Lin-Lin Wang, Rong Deng, Jian-Nan Liu, Gong-Kan Feng, Ding-Jun Xiao, Song-Zhi Deng, Xiao-Shi Zhang, Xiao-Feng Zhu*. Rhabdastrellic acid-A induced autophagy-associated cell death through blocking Akt pathway in human cancer cells. PLos One, 2010, 5(8):e12176

    15. Rong Deng, Jun Tang, Bin-Fen Xie, Gong-Kan Feng, Yue-Han Huang, Zong-Chao Liu, Xiao-Feng Zhu*. SYUNZ-16, a new synthesized alkannin derivative, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of AKT/FOXO signal pathway. Int J Cancer, 2010, 127(1):220-9

    16. Wen-Jun Zhou, Rong Deng, Xiao-Yue Zhang, Gong-Kan Feng, Lian-Quan Gu, Xiao-Feng Zhu*. G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells. Mol Cancer Ther, 2009, 8:3203-3213

    17. Dan-Dan Li, Lin-Lin Wang, Rong Deng, Jun Tang, Yang Shen, Jin-Feng Guo, Yao Wang, Liang-Ping Xia, Gong-Kan Feng, Quentin Q Liu, Wen-Lin Huang, Yi-Xin Zeng, Xiao-Feng Zhu*. The pivotal role of c-Jun-NH2-terminal kinase-mediated Beclin-1 expression during anticancer agents-induced autophagy in cancer cells. Oncogene, 2009, 28, 886-898.

    18. Rong Deng, Jun Tang, Liang-Ping Xia, Dan-Dan Li, Lin-Lin Wang, Gong-Kan Feng, Yi-Xin Zeng, Xiao-Feng Zhu*. ExcisaninA induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway. Mol Cancer Ther, 2009, 8(4): 873-882.

    19. Dan-Dan Li, Xiao-Qi Wu, Ju Tang, Xiao-Yi Wei, Xiao-Feng Zhu*. ON-III inhibits erbB-2 tyrosine kinase receptor signal pathway and triggers apoptosis through induction of Bim in breast cancer cells. Cancer Biology & Therapy, 2009; 8(8):739-43

    20. Hu ZY, Zhu XF(co-first author), Zhong ZD, Sun J, Wang J, Yang D, Zeng YX. ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts. Int J Cancer, 2008, 123(10):2418-29

    21. Yuan XW, Zhu XF*, Liang SG, Fan Q, Chen ZX, Huang XF, Sheng PY, He AS, Yang ZB, Deng R, Feng GK, Liao WM. Interferonalpha enhances etoposide-induced apoptosis in human osteosarcoma U2OS cells by a p53-dependent pathway. Life Sci, 2008, 82(7-8): 393-401

    22. Guo JF, Zhou JM, Zhang Y, Deng R, Liu JN, Feng GK, Liu ZC, Xiao DJ, Deng SZ, Zhu XF*. Rhabdastrellic acid-A inhibited PI3K/Akt pathway and induced apoptosis in human leukemia HL-60 cells. Cell Biol Int. 2008, 32(1):48-54

    23. Xiang-Wei Yuan, Xiao-Feng Zhu*, Wei-Ming Liao. p14ARF sensitizes human osteosar- coma cells to cisplatin-induced apoptosis in a p53-independent manner. Cancer Biology & Therapy, 2007, 6(7): 1074 -1080

    24. Guan Z, Wang XR, Zhu XF (co-first author), Huang XF, Xu J, Wang LH, Wan XB, Long ZJ, Liu JN, Feng GK, Huang W, Zeng YX, Chen FJ, Liu Q. Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res, 2007;67(21):10436-44

    25. Xiang-Wei Yuan, Xiao-Feng Zhu*, Huang XF, Sheng PY, He AS, Yang ZB, Deng R, Feng GK, Liao WM. Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis1. Acta Pharmacol Sin, 2007, 28(11):1835-41.

    26. Yu-Ping Mei, Jun-Min Zhou, Yi Wang, He Huang, Rong Deng, Gong-Kan Feng, Yi-Xin Zeng, Xiao-Feng Zhu*. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle, 2007, 6(11): 1379-1385.

    27. Jian-nan Liu, Rong Deng, Jin-Feng Guo, Jun-Min Zhou, Gong-Kan Feng, Zhi-Shu Huang, Lian-Quan Gu, Yi-Xin Zeng, Xiao-Feng Zhu*.  Inhibition of myc promoter and telomerase activity and induction of delayed apoptosis by SYUIQ-5, a novel G-quadruplex interactive agent in leukemia cells. Leukemia, 2007, 21(6), 1300-1302

    28. Zhi-Yi Cheng, Wen-Jie Li, Feng He, Jun-Min Zhou and Xiao-Feng Zhu*. Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem, 2007, 15(3): 1533-1538

    29. Rong Deng, Wenming Li, Zhong Guan, Jun-Min Zhou, Yi Wang, Yu-Ping Mei, Ming-Tao Li, Gong-Kan Feng, Wenlin Huang, Zong-Chao Liu, Yifan Han, Yi-Xin Zeng and Xiao-Feng Zhu*. Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis.  Oncogene, 2006, 25(53):7070-7

    30. Jun-Min Zhou, Xiao-Feng Zhu*, Yu-Jin Lu, Rong Deng, Zhi-Shu Huang, Yu-Ping Mei, Yi Wang, Wenlin Huang, Zong-Chao Liu, Lian-Quan Gu and Yin-Xin Zeng. Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines. Oncogene, 2006, 25, 503-511

    31. Xiao-Feng Zhu*, Jing-Song Wang, Li-Ling Cai, Yi-Xin Zeng and Dajun Yang. SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G phase in breast cancer cells. Cancer Science, 2006, 97(1): 84-89

    32. Yu-Ping Mei, Xiao-Feng Zhu*, Jun-Min Zhou, He Huang, Rong Deng, Yi-Xin Zeng. siRNA targeting LMP1-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression. Cancer Letters, 2006, 232, 189-198

    33. Jin-Jun Zhu, Fu-Bo Li, Xiao-Feng Zhu*, Wei-Ming Liao. The p33(ING1b) tumor suppressor cooperates with p53 to induce apoptosis in response to etoposide in human osteosarcoma cells. Life Sciences, 2006, 78(13):1469-77

    34. Xiao-Feng Zhu, Bin-Fen Xie, Jun-Min Zhou, Gong-Kan Feng, Zong-Chao Liu, Xiao-Yi Wei, Feng-Xian Zhang, Mei-Fang Liu and Yi-Xin Zeng. Blockade of VEGF receptor signal pathway and antitumor activity of ON-III, a component from Chinese herbal medicine. Mol Pharmacol, 2005, 67(5):1444-1450.

    35. Jin-Jun Zhu, Fu-Bo Li, Jun-Min Zhou, Zong-Chao Liu, Xiao-Feng Zhu*, Wei-Ming Liao. The Tumor Suppressor p33(ING1b) Enhances Taxol-induced Apoptosis by p53-Dependent Pathway in Human Osteosarcoma U2OS Cells. Cancer Biol Ther, 2005, 4(1):39-47.

    36. Zong-Wei Wang, Jun-Min Zhou, Zhi-Shu Huang, Ai-Ping Yang, Zong-Chao Liu, Yun-Fei Xia, Yi-Xin Zeng, Xiao-Feng Zhu*. Aloe polysaccharides mediated radioprotective effect through the inhibition of apoptosis. J Radiat Res, 2004, 45 (3): 447-454.

    37. Xiao-Feng Zhu, Zong-Chao Liu, Bin-Fen Xie, Yi-Xin Zeng. Ceramide induces cell cycle arrest and upregulates p27kip in nasopharyngeal carcinoma cells. Cancer Letters, 2003, 193(2):149-155.

    38. Xiao-Feng Zhu, Zong-Chao Liu, Bin-Fen Xie, Zhi-Min Li, Gong-Kan Feng, Hai-Hiu Xie, Shu-Jun Wu, Ren-Zhou Yang, Xiao-Yi Wei, Yi-Xin Zeng. Involvement of Caspase-3 Activation in Squamocin-induced Apoptosis in Leukemia Cell line HL-60. Life Sciences, 2002, 70(11):1259-1269.

    39. Xiao-Feng Zhu, Zong-Chao Liu, Bin-Fen Xie, Zhi-Min Li, Gong-Kan Feng, Dajun Yang, Yi-Xin Zeng. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cell line CNE2.  Cancer Letters, 2001, 169 (1): 27-32.

    40. Xiao-Feng Zhu, Xiao-Shi Zhang, Zhi-Min Li, Yu-Qi Yao, Bin-Fen Xie, Zong-Chao Liu, Yi-Xin Zeng. Apoptosis induced by ceramide in hepatocellular carcinoma Bel7402 cells. Acta Pharmacol Sin, 2000, 21(3):225-8

    41. Huang JJ, Li HR, Huang Y, Jiang WQ, Xu RH, Huang HQ, Lv Y, Xia ZJ, Zhu XF, Li ZM. Beclin 1 expression: a predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type. Autophagy, 2010, 6: 777-83

    42. Chen J, Hu CF, Hou JH, Shao Q, Yan LX, Zhu XF, Zeng YX, Shao JY. Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma. J Transl Med, 2010, 8: 30

    43. Du ZM, Hu CF, Shao Q, Huang MY, Kou CW, Zhu XF, Zeng YX, Shao JY. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer, 2009, 125(8):1832-41.

    44. Hu ZY, Sun J, Zhu XF, Yang D, Zeng YX. ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway.  J Transl Med, 2009; 7:74.

    45. Li JJ, Ding Y, Li DD, Peng RQ, Feng GK, Zeng YX, Zhu XF, Zhang XSThe overexpression of ERCC-1 is involved in the resistance of lung cancer cells to cetuximab combined with DDP. Cancer Biol Ther, 2009, 8: 1914-21

    46. Jia HY, Wu JX, Zhu XF, Chen JM, Yang SP, Yan HJ, Tan L, Zeng YX, Huang W. ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells. Leuk Res, 2009, 33(11):1512-9

    47. Li BX, Li CY, Peng RQ, Wu XJ, Wang HY, Wan DS, Zhu XF, Zhang XS. The expression of beclin 1 is associated with favorable prognosis in stage IIIB colon cancers. Autophagy, 2009, 5(3):303-6

    48. Li HL, Li S, Shao JY, Lin XB, Cao Y, Jiang WQ, Liu RY, Zhao P, Zhu XF, Zeng MS, Guan ZZ, Huang W. Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors. Gene Ther, 2008,15(4):247-56

    49. Wan XB, Long ZJ, Yan M, Xu J, Xia LP, Liu L, Zhao Y, Huang XF, Wang XR, Zhu XF, Hong MH, Liu Q. Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis, 2008, 29(10):1930-7

    50. Li Y, Shao JY, Liu RY, Zhou L, Chai LP, Li HL, Han HY, Huang BJ, Zeng MS, Zhu XF, Liu Q, Fu LW, Huang W. Evaluation of long-term toxicity of Ad/hIFN-, an Adenoviral vector encoding the human interferon-gamma gene, in nonhuman primates. Hum Gene Ther, 2008,19(8):827-39

    51. Wang LH, Yan M, Xu DZ, Cao JX, Zhu XF, Zeng YX, Liu Q. Requirement of aurora-A kinase in astral microtubule polymerization and spindle microtubule flux. Cell Cycle. 2008, 7(8):1104-11

    52. Zhang NH, Song LB, Wu XJ, Li RP, Zeng MS, Zhu XF, Wan DS, Liu Q, Zeng YX, Zhang XS.Proteasome inhibitor MG-132 modifies coxsackie and adenovirus receptor expression in colon cancer cell line lovo. Cell Cycle, 2008, 7(7):925-33

    53. Li ZM, Jiang WQ, Zhu ZY, Zhu XF, Zhou JM, Liu ZC, Yang DJ, Guan ZZ. Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells. Cancer Biol Ther, 2007, 8;7(1): 56-60

    54. Xiao X, Wu J, Zhu X, Zhao P, Zhou J, Liu QQ, Zheng L, Zeng M, Liu R, Huang W. Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer, 2007, 121(9):2095-104.

    55. Jiangxue Wu, Xia Xiao, Peng Zhao, Gang Xue, Yinghui Zhu, Xiaofeng Zhu, Limin Zheng, Yixin Zeng and Wenlin Huang. Minicircle-IFNgamma induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma. Clin Cancer Res, 2006, 12(15):4702-13.

    56. Jin-Lin Zhou, Yu-Jing Lu, Tian-Miao Ou, Jun-Min Zhou, Zhi-Shu Huang, Xiao-Feng Zhu, Cui-Juan Du, Xian-Zhang Bu, Lin Ma, Lian-Quan Gu, Yue-Ming Li, and Albert Sun-Chi Chan. Synthesis and evaluation of quindoline derivatives as G-quadruplex inducing and stabilizing ligands and potential inhibitors of telomerase. J Med Chem, 2005, 48(23):7315-21.

    57. Wenzhe Ma, Yicun Huang, LiDong Lin, Xiaofeng Zhu, Yizhu Chen, Hanhong Xu and Xiaoyi Wei. Two new biologically  active illudane  sesquiterpenes from the  mycelial  cultures of Panaeolus retirugis. J Antibiot, 2004, 57(11):721-5.

    58. Ning-Ning Zhou, Xiao-Feng Zhu, Jun-Min Zhou, Zhi-Min Li, Xiao-Shi Zhang, Peng Huang, Wen-Qi Jiang. 2-Methoxyestradiol induces cell cycle arrest and apoptosis of nasopharyngeal carcinoma cells. Acta Pharmacol Sin, 2004, 25(11):1515-20

    59. Jun-Min Zhou, Xiao-Feng Zhu, Qi-Chao Pan, Duan-Fang Liao, Zhi-Min Li, Zong-Chao Liu. Manumycin inhibits cell proliferation and Ras signal transduction pathway in human heptocellular carcinoma cells. Int J Mol Med, 2003, 11(6):767:71

    60. Jun-Min Zhou, Xiao-Feng Zhu, Qi-Chao Pan, Duan-Fang Liao, Zhi-Min Li, Zong-Chao Liu. Manumycin induced apoptosis in human heptocellular carcinoma cells. Int J Mol Med, 2003, 12(6):955-9.

    61. Xiao-Shi Zhang, Xiao-Feng Zhu, Jin-Song Gao, Yan-li Ye, Qi-Sheng Feng, Zong-Chao Liu, Yi-Xin Zeng. Variable sensitivity of endothelial cells to epirubicin in xenografts of human nasopharyngeal carcinoma CNE2 cells. Cancer Biol Ther, 2002, 1(3): 263-265

    62. Istvan J. Enyedy, Yan Ling, Kassoum Nacro, York Tomita, Xihan Wu, Yeyu Cao, Ribo Guo, Bihua Li, Xiaofeng Zhu, Ying Huang, Ya-Qiu Long, Peter P. Roller, Dajun Yang and Shaomeng Wang. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem, 2001, 44(25):4313-24.

    63. Terrence R. Burke Jr., Zhu-Jun Yao, Yang Gao, Jane X. Wu, Xiaofeng Zhu, Juliet H. Luo, Ribo Guo and Dajun Yang. N-terminal carboxyl and tetrazole-containing amides as adjuvants to Grb2 SH2 domain ligand binding. Bioorg Med Chem, 2001, 9(6): 1439-1445

    64. Xiao-Shi Zhang, Xiao-Feng Zhu, Jin-Song Gao, Chao-Nan Qian, Zhu-Ji Kuang, Zong-Chao Liu, Yi-Xin Zeng. Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165. Acta Pharmacol Sin, 2001, 22 (8): 731-736

    Tiebang Kang
    Title Professor, Principle Investigator and Deputy Chair

    Prof. Tiebang Kang is a deputy chair of Dept of Experimental Research, and a principle investigator and professor of Sun Yat-sen University Cancer Center. He gained his Ph.D. degree at Bielefeld University in 2003 and had his Post-doc training in MD Anderson Cancer Center and Washington University in St. Louis from 2004 to 2008. Dr. Kang moved back to China to start his lab in 2008. Dr. Kang was awarded as a Distinguished Professor from NCSF and Ministry of Education of China in 2011 and 2014, respectively. In 2019, Dr. Kang was awarded as a Distinguished Scholar Professor of Guangdong province.

    Research Interest(s)

    Dr. Kang’s laboratory majorly engages in the cell cycle regulation, exosomes and metastasis. The main theme in his lab is to identify new targets to overcome the drug resistance for cancer treatments and/or to improve the outcomes of cancer patients with metastases, and to illustrate how these targets execute their intracellular functions and/or their secretion into exosomes to modulate the tumor microenvironment.


    1992   Clinical laboratory Medicine
    Hunan Medical University, Changsha, China

    1996  M.S. in Biochemistry
    Guangdong Medical College, Zhanjiang, China

    2003  Ph.D. in Biochemistry
    Bielefeld University, Germany

    2004-2008  Postdoc in Molecular Oncology
    MD Anderson Cancer Center and Washington University in St. Louis, USA


    10 representative publications:
    1. Wei D#, Zhan W#, Gao Y#, Huang L, Gong R, Wang W, Zhang R, Wu Y, Gao S, Kang T* RAB31 marks and controls an ESCRT-independent exosome pathway. Cell Res. 2021 Feb, 31(2), 157–177.(IF: 20.50)

    2. Zhong L#, Liao D#, Li J#, Liu W, Wang J, Zeng C, Wang X, Cao Z, Zhang R, Li M, Jiang K, Zeng YX, Sui J*, Kang T*. Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes. Signal Transduct Target Ther. 2021 Feb 11; 6(1):59.(IF: 13.49)

    3. Liao D#, Zhong L#, Yin J#, Zeng C, Wang X, Huang X, Chen J, Zhang H, Zhang R, Guan XY, Shuai X, Sui J, Gao S, Deng W, Zeng YX, Shen J*, Chen J*, Kang T* Chromosomal Translocation-derived Aberrant RAB22A Drives Osteosarcoma Metastasis. Nature Cell Biol, July 2020, 22, 868–881.(IF: 20.04)

    4. Zhou L, Zheng L, Hu K, Wang X, Zhang R, Zou Y, Zhong L, Wang S, Wu Y*, Kang T* SUMOylation Stabilizes hSSB1 and Enhances the Recruitment of NBS1 to DNA Damage Sites. Signal Transduct Target Ther. 2020 Jun 24; 5(1):80.(IF: 13.49)

    5. Wang x, Qin G, Liang X, Wang Z, Liao D, Zhong L, Zhang R, Zeng YX, Wu Y*, Kang T* Targeting the CK1α/CBX4 Axis for Metastasis in Osteosarcoma. Nat Commun, 2020 Feb 28; 11, 1141.(IF:12.12)

    6. Liao D, Zhong L, Duan T, Zhang RH, Wang X, Wang G, Hu K, Lv X, Kang T* Aspirin suppresses the growth and metastasis of osteosarcoma through the NF-kB pathway. Clin Cancer Res, 2015 Dec 1; 21, 5349-59.(IF: 10.10) 

    7. Wu Y#, Chen H#, Lu J, Zhang M, Zhang R, Duan T, Wang X, Huang J*, Kang T* Acetylation-dependent function of human single-stranded DNA binding protein 1(hSSB1). Nucleic Acids Res. 2015 Sep 18; 43(16):7878-87.(IF: 11.50)

    8. Xu S#, Wu Y#, Chen Q, Cao J, Hu K, Tang J, Sang Y, Lai F, Wang L, Zhang R, Li S-P, Zeng Y-X, Yin Y, Kang T* hSSB1 regulates both the stability and the transcriptional activity of p53. Cell Res. 2013 Mar; 23(3): 423-35.(IF: 20.50)

    9. Hong J#, Hu K#, Yuan Y*, Sang Y, Bu Q, Chen G, Yang L, Li B, Huang P, Chen D1, Liang Y, Zhang R, Pan J, Zeng YX, Kang T* Chk1 Targets Spleen Tyrosine Kinase (L) for Proteolysis in Hepatocellular Carcinoma. J Clin Invest. 2012 Jun; 122(6): 2165-75.(IF: 11.86)

    10. Tang QL#, Xie XB#, Wang J#, Chen Q, Han AJ, Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, Yong BC, Zhang RH, Feng QS, Deng WD, Zhu XF, Zhou BP, Zeng YX1, Shen JN*, and Kang T* Glycogen Synthase Kinase-3β, NF-κB Signaling, and Tumorigenesis of Osteosarcoma. J Natl Cancer Inst. 2012 May 16; 104(10): 749-63.(IF: 11.57)

    Updated March 2021

    Song Gao
    Title Deputy Director and Professor

    Dr. Song Gao is professor of structural biology in SYSUCC. Dr. Gao obtained his Bachelor degree in biotechnology at Wuhan University, 2005. He then went to Europe for graduate study and obtained Master degree in Structural proteomics at University of St Andrews in UK, 2006 and Doctor degree with “Summa Cum Laude” at Max-Delbrück-Centrum for Molecular Medicine (MDC)/Freie Universtät Berlin, Germany, 2011. During his time in Germany, he started to investigate the functional mechanisms of dynamin superfamily. After a short period of postdoc training in MDC, Dr. Gao was granted the National Recruitment Program of Global Youth Experts and moved to SYSUCC to start his own research group in 2012. In SYSUCC, Dr. Gao has established a multi-disciplinary research platform which combines structural biology with single-molecule biophysics, biochemistry and cell biology. Dr. Gao is currently supported by several research grants from the National Natural Science Foundation of China, National Basic Research Program of China, and Natural Science Foundation of Guangdong Province. The research of Dr. Gao’s group is focused on (1) Molecular basis of membrane remodelling mediated by dynamin superfamily, and (2) RNA-manipulating enzymes involved in tumorigenesis and metastasis.

    Research Interest(s)

    1. Molecular basis of membrane remodelling mediated by dynamin superfamily

    Members of the dynamin superfamily catalyze fission and fusion of various   membrane-remodeling proteins that are responsible for many fundamental cellular events in eukaryotes, such as endocytosis, mitochondrial dynamics, and resistance to certain viruses. Malfunction of these proteins causes various human diseases, including neurodegenaration, diabetes and cancer. Dynamin family proteins are multi-domain GTPases which catalyse membrane fission and fusion through orchestrated GTP hydrolysis and self-oligomerization.
        Our group is working on the functional mechanisms of the dynamin superfamily. We use a variety of techniques, including X-ray crystallography, single-molecule biophysics, as well as biochemistry and cell biology methods to investigate how dynamin family members mediate membrane remodeling, and what is the structural difference between the fission- and fusion-related members. Particularly, we focus on the MxA protein which represents the fission dynamins, and mitofusins that are involved in mitochondrial outer membrane fusion.

    2. RNA-manipulating enzymes involved in tumorigenesis and metastasis
    The development of modern sequencing techniques has helped to reveal various genes or transcripts that are involved in tumorigenesis and metastasis. Some of them encode proteins with undefined biochemical function. In many cases, these proteins show no sequence homology to other known protein families, and are therefore difficult to characterize.
        We start from revealing the structures of these unknown proteins, and aim to find out the hidden kinship between these proteins and other known proteins by their folding pattern. This three-dimensional strategy enables us to accurately define the biochemical function of given known proteins. Of these candidates, we are particularly interested in enzymes involved in RNA manipulation. Up to know, we have identified several novel endoribonucleases and nucleotidyl transferases related to cancer. By systematic functional characterization of these potential drug targets, our research provides important insights that contribute to the development of corresponding approaches against cancer.


    2007-2011: PhD at Max-Delbrück-Centrum for Molecular Medicine (MDC)/Freie Universtät Berlin, Germany (with “Summa Cum Laude”).

    2005-2006: MRes in Structural Proteomics, School of Biology, University of St Andrews, UK.

    2001-2005: BSc in Biotechnology in College of Life Sciences, Wuhan University, P. R. China.


    Selected publications:
    1. Yu-Lu Cao, Shuxia Meng, Yang Chen, Jian-Xiong Feng, Dong-Dong Gu, Bing Yu, Yu-Jie Li, Jin-Yu Yang, Shuang Liao, David C. Chan, Song Gao. MFN1 structures reveal nucleotide-triggered dimerization critical for mitochondrial fusion. Nature 2017, 542(7641):372-376

    2. Yang Chen, Lei Zhang, Laura Graf, Bing Yu, Yue Liu, Georg Kochs, Yongfang Zhao, Song Gao. Conformational dynamics of dynamin-like MxA revealed by single-molecule FRET. Nature Communications 2017, 8:15744

    3. Song Gao, Alexander von der Malsburg, Alexej Dick, Katia Faelber, Gunnar F. Schröder, Otto Haller, Georg Kochs, Oliver Daumke. Structure of myxovirus resistance protein a reveals intra- and intermolecular domain interactions required for the antiviral function. Immunity 2011, 35(4):514-525

    4. Katja Faelber, York Posor, Song Gao, Martin Held, Yvette Roske, Dennis Schulze, Volker Haucke, Frank Noé, Oliver Daumke. Crystal structure of nucleotide-free dynamin. Nature 2011, 477(7366):556-560

    5. Song Gao, Alexander von der Malsburg, Susann Paeschke, Joachim Behlke, Otto Haller, Georg Kochs, Oliver Daumke. Structural basis of oligomerization in the stalk region of dynamin-like MxA. Nature 2010, 465(7297):502-506

    6. Chee Seng Hee#, Song Gao#, Bernhard Loll, Marcia M. Miller, Barbara Uchanska-Ziegler, Oliver Daumke, Andreas Ziegler. Structure of a classical MHC class I molecule that binds "non-classical" ligands. PLoS Biology 2010, 8(12):e1000557

    Jin-Xin Bei
    Title Professor and Deputy Director
    Dr. Bei obtained his B.S. and Ph.D. degrees from Sun Yat-sen University, Guangzhou, China. Right after that the joined Sun Yat-sen University Cancer Center (SYSUCC) as a postdoc and Genome Institute of Singapore (GIS) as visiting research fellow. He returned to SYSUCC after years of working as research scientist at GIS. His major research interest is to dissect genetic and pathogenic factors contributing to the development of cancers, as well as the underlying mechanisms. He has published more than 100 scientific papers including those in prestigious journals such as Cell, Nat Genet, Lancet Oncol, etc. He has track-records in organizing large international collaborations. 
    Research Interest(s)
    Cancer is a complex disease involving genetic susceptibility and acquired alterations invoked by pathogen infection and environmental exposures, which jointly foster a heterogeneous niche for tumor initiation, progression, and resistance to treatments. My major research interest is to dissect the germline variations and the acquired alterations of either host and pathogens at different dimensions as well as to uncover the underlying mechanisms by which they contribute to the heterogeneous nature of incidence, progression, and treatment resistance of cancers. We have mainly used Epstein-Barr Virus (EBV) related malignancies as working models, such as Nasopharyngeal Carcinoma (NPC), Natural Killer/T cell lymphoma (NKTCL), etc, with particular interest on resolving the details of their associations with ubiquitous EBV and remarkable prevalence in Southern China. Our group has established high throughput data generation and analysis platform, which empowers novel discoveries with genome-wide genetic data, transcriptome, epigenetic data at bulk tissue/cells or single-cell levels. The clinical and follow-up information are collected for association analyses to reveal the key genes/pathways that contribute to the incidence and the clinical outcomes of cancers, such as cancer risk, drug response, prognosis, and survival. International collaboration has been a general practice in my group to synergize colleagues of different expertise and resource. 
    Education Current Professional Appointments
    Joint Professor, Department of Medical Oncology, National Cancer Centre, Singapore.
    Professor and Principal Investigator, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, China
    Director, core facility of biomedical research, Center for Precision Medicine, Sun Yat-sen University Cancer Center, China

    Academic Appointments
    2020 - present, Editor, Journal of Genetics and Genomics
    2019 – present, member of the Youth Committee of the Chinese Anti-Cancer Association
    2018 – present, Vice Chairman, Medical Genetics Committee of the Association of Medicine in Guangdong
    2017 – present, Standing Committee Member of the Asia-Pacific Association of Medicine and Bio-Immunology
    2017 – present, Associate Editor, Journal of Gene Medicine
    2017 – present, Editorial Board member, Annals of Nasopharynx Cancer
    2015, member of the Scientific International Committee, the7th Biannual Nasopharyngeal Carcinoma
    2013 – present, member of the Youth Committee of the Genetics Society of China
    2012 – present, Managing Editor, Cancer Communications (previously known as Chinese Journal of Cancer)
    2012 – present, member of Chinese Cancer Genome Consortium
    2012 – present, member of International Cancer Genome Consortium (NPC)
    Five representative publications within the last five years: (*corresponding author)
    1. Luo CL, Xu XC, Liu CJ, He S, Chen JR, Feng YC, Liu SQ, Peng W, Zhou YQ, Liu YX, Wei PP, Li B, Mai HQ, Xia XJ, Bei JX*. RBFOX2/GOLIM4 Splicing Axis Activates Vesicular Transport Pathway to Promote Nasopharyngeal Carcinogenesis. Advanced Science 8, 2004852 (2021).

    2. Ren X, Wen W, Fan X, Hou W, Su B, Cai P, Li J, Liu Y, Tang F, Zhang F, Yang Y, He J, Ma W, He J, Wang P, Cao Q, Chen F, Chen Y, Cheng X, Deng G, Deng X, Ding W, Feng Y, Gan R, Guo C, Guo W, He S, Jiang C, Liang J, Li YM, Lin J, Ling Y, Liu H, Liu J, Liu N, Liu SQ, Luo M, Ma Q, Song Q, Sun W, Wang G, Wang F, Wang Y, Wen X, Wu Q, Xu G, Xie X, Xiong X, Xing X, Xu H, Yin C, Yu D, Yu K, Yuan J, Zhang B, Zhang P, Zhang T, Zhao J, Zhao P, Zhou J, Zhou W, Zhong S, Zhong X, Zhang S, Zhu L, Zhu P, Zou B, Zou J, Zuo Z, Bai F, Huang X, Zhou P*, Jiang Q*, Huang Z*, Bei JX*, Wei L*, Bian XW*, Liu X*, Cheng T*, Li X*, Zhao P*, Wang FS*, Wang H*, Su B*, Zhang Z*, Qu K*, Wang X*, Chen J*, Jin R*, Zhang Z*. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell 184, 1895 (2021).

    3. Liu Y, He S, Wang XL, Peng W, Chen QY, Chi DM, Chen JR, Han BW, Lin GW, Li YQ, Wang QY, Peng RJ, Wei PP, Guo X, Li B, Xia X, Mai HQ, Hu XD, Zhang Z*, Zeng YX* & Bei JX*. Tumour Heterogeneity and Intercellular Networks of Nasopharyngeal Carcinoma at Single Cell Resolution. Nat Commun 12, 741 (2021).

    4. Guo YM, Chen JR, Feng YC, Chua MLK, Zeng Y, Hui EP, Chan AKC, Tang LQ, Wang L, Cui Q, Han HQ, Luo CL, Lin GW, Liang Y, Liu Y, He ZL, Liu YX, Wei PP, Liu CJ, Peng W, Han BW, Zuo XY, Ong EHW, Yeo ELL, Low KP, Tan GS, Lim TKH, Hwang JSG, Li B, Feng QS, Xia X, Xia YF, Ko J, Dai W, Lung ML, Chan ATC, Lo DYM, Zeng MS, Mai HQ*, Liu J*, Zeng YX* & Bei JX*. Germline Polymorphisms and Length of Survival of Nasopharyngeal Carcinoma: An Exome-Wide Association Study in Multiple Cohorts. Advanced Science7, 1903727 (2020). 

    5. Lin GW, Xu C, Chen K, Huang HQ, Chen J, Song B, Chan JKC, Li W, Liu W, Shih LY, Chuang WY, Kim WS, Tan W, Peng RJ, Laurensia Y, Cheah DMZ, Huang D, Cheng CL, Su YJ, Tan SY, Ng SB, Tang TPL, Han K, Wang VY, Jia WH, Pei Z, Li YJ, Gao S, Shi Y, Hu Z, Zhang F, Zhang B, Zeng YX, Shen H, He L, Ong CK, Lim ST, Chanock S, Kwong YL, Lin D, Rothman N, Khor CC, Lan Q & Bei JX*. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol 21, 306 (2020).

    Updated September 2021
    Fu Li-wu
    Title Professor

    Li-wu Fu, Ph.D., Professor, Doctoral Supervisor. Prof. Fu obtained his PhD in the field of Cancer Pharmacology from the Sun Yat-sen University and carried out his doctoral research in South Carolina Medical University from 1999 to 2001. 

    Prof. Fu’s field of expertise includes anticancer drug pharmacology, molecular mechanism of anticancer drugs and individual cancer chemotherapy. In recent years, he mainly focused on the study of molecular mechanism of anti-cancer drugs, drug resistance of cancer cells (especially multidrug resistance), the innate resistance of cancer stem cells and the individual cancer chemotherapy. For the excellent work in the research of “Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells”, Prof. Fu’s team gained the first prize of “Chinese Anti-Cancer Association (CACA) Science and Technology Award” (Ranked first) and the second prize of “Institute of Higher Education Outstanding Scientific Research Achievements Award” (Natural Science Award) in 2011. 

    As the leader of the research group, he has won the provincial and ministerial level scientific and technological awards for several times, including the “Outstanding young scientific and technological talents award from Ministry of Health”, the “Servier outstanding young workers Pharmacology Award” and the “Ding Ying Science Award” in 2011. 

    Prof. Fu has presided over and successfully completed more than 40 key research projects on national, provincial and ministerial scale and horizontal fund projects. 

    More than 200 research papers have been published and up to 100 papers have been published in high-quality SCI journals, including Cancer Res (6 articles), Oncotarget, Mol Med, Cell Cycle, Eur J Cancer, Mol Cancer Ther, Birth J Parmacol, Biochem Pharmacol , Mol Pharmacol etc. and 10 invention patents have been attained.

    Research Interest(s)

    1. Screening of tumor multi-drug resistance reversal agents and mechanism research 

    2. Development and research of novel chemotheraputic drugs.

    3. Developing tumor chemosensitivity testing system to realize individualized chemotherapy

    For information on Professor Fu's laboratory, click here and select: Research on anticancer drugs.

    1982-1987 M.D. Degree from Guangdong Medical and Pharmaceutical College, Guangdong, China.

    1990-1993 Master degree from Sun Yat-Sen University of Medical Sciences, Guangdong, China. 

    1993-1996 Ph.D. degree from Sun Yat-Sen University of Cancer Center, Guangdong, China.

    1999-2002 Postdoctoral Associate at South Carolina Medical University, United States.


    1.Wang XK, He JH, Xu JH, Ye S, Wang F, Zhang H, Huang ZC, To KK, Fu LW*. Afatinib Enhances the Efficacy of Conventional Chemotherapeutic Agents by Eradicating Cancer Stem-like Cells. Cancer Res. 2014 Jun 27. [Epub ahead of print] (IF:9.28)

    2. Zhu H, Zhang H, Jin F, Fang M, Huang M, Yang CS, Chen T, Fu L*, Pan Z*. Elevated Orai1 expression mediates tumor-promoting intracellular Ca2+ oscillations in human esophageal squamous cell carcinoma. Oncotarget. 2014 Jun 15;5(11):3455-71. (IF:6.63)

    3. Zhang H, Wang YJ, Zhang YK, Wang DS, Kathawala RJ, Patel A, Talele TT, Chen ZS, Fu LW*. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Cancer Lett. 2014 Aug 1;350(1-2):61-8. (IF:5.02)

    4. Hong J, Liu Z, Zhu H, Zhang X, Liang Y, Yao S, Wang F, Xie X, Zhang B, Tan T, Fu L*, Nie J*, Cheng C*. The tumor suppressive role of NUMB isoform 1 in esophageal squamous cell carcinoma. Oncotarget. 2014 Jun 26. [Epub ahead of print] (IF:6.63)

    5. Liu KJ, He JH, Su XD, Sim HM, Xie JD, Chen XG, Wang F, Liang YJ, Singh S, Sodani K, Talele TT, Ambudkar SV, Chen ZS, Wu HY, Fu LW*. Saracatinib (AZD0530) is a potent modulator of ABCB 1-mediated multidrug resistance in vitro and in vivo. Int J Cancer. 2013 Jan 1;132(1):224-35. (IF=6.20)

    6. Hu YP, Tao LY, Wang F, Zhang JY, Liang YJ, Fu LW*. Secalonic acid D reduced the percentage of side populations by down-regulating the expression of ABCG2. Biochem Pharmacol. 2013 Jun 1;85(11):1619-25. (IF=4.65)

    7. Zhao XQ, Xie JD, Chen XG, Sim HM, Zhang X, Liang YJ, Singh S, Talele TT, Sun Y, Ambudkar SV, Chen ZS, Fu LW*. Neratinib Reverses ATP-Binding Cassette B1-Mediated Chemotherapeutic Drug Resistance In Vitro, In Vivo, and Ex Vivo. Mol Pharmacol. 2012; 82(1):47-5

    8. (IF=4.78)8. Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng XX, Abraham I, Ambudkar SV, Talele TT, Fu LW*, Chen ZS*. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res. 2011; 71(8):3029-41. (IF:9.28)

    9.Wang F, Liang YJ, Wu XP, Chen LM, To KK, Dai CL, Yan YY, Wang YS, Tong XZ, Fu LW*. Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia. Eur J Cancer. 2011; 47(13):1990-9. (IF=5.54)

    10. Yan YY, Zheng LS, Zhang X, Chen LK, Singh S, Wang F, Zhang JY, Liang YJ, Dai CL, Gu LQ, Zeng MS, T Talele T, Chen ZS, Fu LW*. Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu. Mol Pharm. 2011; 8(5):1687-97. (IF=5.4)

    11. Shi Z, Tiwari AK, Patel AS, Fu LW*, Chen ZS*. Roles of sildenafil in enhancing drug sensitivity in cancer. Cancer Res. 2011; 71(11):3735-8. (IF:9.28) (Review)

    12. Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, Ma XX, To KK, Ambudkar SV, Chen ZS, Fu LW*. Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters. Cancer Res. 2010; 70(20):7981-91. (IF:9.28)

    13. Zhang JY, Tao LY, Liang YJ, Yan YY, Dai CL, Xia XK, She ZG, Lin YC, Fu LW*. Secalonic acid D induced leukemia cell apoptosis and cell cycle arrest of G(1) with involvement of GSK-3beta/beta-catenin/c- Myc pathway. Cell Cycle. 2009; 8(15):2444-50. (IF=5.0)

    14. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby Jr. CR, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW*. Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Res. 2008; 68(19):7905-7914. (IF:9.28)

    15.Yan YY, Su XD, Liang YJ, Zhang JY, Shi CJ, Lu Y, Gu LQ, Fu LW*. Emodin azide methyl anthraquinone derivative triggers mitochondrial-dependent cell apoptosis involving in caspase-8-mediated Bid cleavage. Mol Cancer Ther. 2008; 7(6):1688-97. (IF=6.11)

    16. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW*, Ambudkar SV, Chen ZS*. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 2007; 67(22):11012-20. (IF:9.28)


    Last updated on: August, 2014

    Wang Hui-Yun
    Title Professor, Director of Lab. of Bionomics and Tumor Marker
    Dr. Hui-Yun Wang is a professor in Basic Oncology and Director of Laboratory of Bionomics and Tumor Marker, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center. He obtained his Bachelor in Medicine (equivalent to MD in the US) at Hengyang Medical College in 1982, and PhD at Sun Yat-sen University of Medical Sciences (SUMS), China, in 1997, when he was appointed as Vice Director of Department of Tumor Pathology, Cancer Institute, SUMS. In 1990’s, he proposed and implemented the project "Locating and Cloning of Nasopharyngeal Carcinoma Susceptibility Gene", which result was published in Nature Genetics (2002). Then, he got his postdoctoral training at the Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey in 2000 – 2003, and then he was promoted to Adjunct Assistant Professor. During the period, he developed a novel microarray technology consisting of over 1000 multiplex PCR and single-base extension assay, which can genotype SNPs from one single sperm and profile gene expression on one single cell, which was published in Genome Research (2005). In Match 2007, he returned to the Sun Yat-Sen University as a professor of the “Hundred Talent Plan”. Since then, he developed various microarrays, including SNP array, microRNA array, gene array, lncRNA array and protein array. With these microarrays, he explored several kinds of tumors including hepatocellular carcinoma (Clin Cancer Res, 2013) and nasopharyngeal carcinoma (Lancet Oncology, 2012). Dr. Wang has published more than 70 research papers.
    Research Interest(s)

    1) Molecular Cancer Genetics: With high-throughput methods, Prof. Wang study the effects of alterations of molecular genetics in cancer, including loss of heterozygosity, DNA copy number change and DNA mutation, on cancer development and progression, and identify oncogenes and tumor suppressors, which are significantly associated with diagnosis, treatment and prognosis of cancer patients. 

    2) Cancer epigenetics: With the custom miRNA and lncRNA microarrays, Prof. Wang have profiled or have been profiling miRNA and lncRNA expressions in cancer and identify the expression signatures associated with diagnosis, therapeutic response and prognosis of cancer patients. He also studies the biological functions and targets of key miRNAs as well as molecular mechanism of lncRNAs in carcinogenesis. 

    3) Tumor Serum marker: With the custom miRNA, lncRNA and EBV protein microarrays, Prof. Wang detects serum miRNA, lncRNA and anti-EBV antibody levels in cancer patients and identify the serum biomarkers for diagnosis, therapeutic response, recurrence, metastasis and prognosis in cancer patients, which will provide new and non-invasive approaches for clinical practice.


    1978.03–1982.12: Bachelor in Medicine (equivalent to MD), Hengyang Medical College, Hunan Province, China. 

    1987.09–1990.06: Master of Science in Basic Oncology, Graduate School, SUMS, Guangzhou, China

    1993.09–1997.11: Ph.D. in Basic Oncology, Graduate School, SUMS, Guangzhou, China

    2000.02–2002.09: Postdoctoral Follow, the Cancer Institute of New Jersey/Dept. of Molecular Genetics & Microbiology, Robert Wood Johnson Medical School, UMDNJ, New Jersey, USA.


    1.         Zheng HQ, Sheng MH, Cha YL, Li WY,Blanco MA, Ren GG, Zhou TH, Storz P, Wang HY, Kang YB. PKD1phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulatesepithelial-mesenchymal transition and metastasis. Cancer Cell, 2014 (inpress).

    2.         PengHS, Liao MB, Zhang MY, Xie Y, Xu L, Zhang YJ, Zheng XF, Wang HY (co-corresponding), Chen YF. Synergistic inhibitoryeffect of hyperbaric oxygen combined with sorafenib on hepatoma cells. PLoSOne. 2014 Jun 23; 9(6): e100814.

    3.         HeL, Wang HY (co-corresponding), Zhang L, Huang L, Li JD, Xiong Y,Zhang MY, Jia WH, Yun JP, Luo RZ, Zheng M. Prognostic significance of low DICERexpression regulated by miR-130a in cervical cancer. Cell Death Dis. 2014 May1; 5:e1205.

    4.         XieY, Wei RR, Huang GL, Zhang MY, Yuan YF, WangHY. Checkpoint kinase 1 is negatively regulated by miR-497 inhepatocellular carcinoma. Med Oncol. 2014 Mar; 31(3):844. Epub2014 Jan 25.

    5.         ZhangJX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, ZhaoHW, Chen W, He YL, Wang HY,Xie D, Luo JH. Prognostic and predictive value of a microRNA signature in stageII colon cancer: a microRNA expression analysis. Lancet Oncol. 2013 Dec; 14(13):1295-306.[Epub 2013 Nov 12]

    6.         YangQ, Luo GY, Li Y, Shan HB, Wang HY (co-corresponding), Xu GL. Expression of Rac-1 relatedto tumor depth, lymph node metastasis and patient prognosis in esophagealsquamous cell carcinoma. Med Oncol. 2013 Dec; 30(4):689. Epub2013 Sep 12.

    7.         HuangL, Wang HY, Li JD, Wang JH,Zhou Y, Luo RZ, Yun JP, Zhang Y, Jia WH, Zheng M. KPNA2 promotes cellproliferation and tumorigenicity in epithelial ovarian carcinoma throughupregulation of c-Myc and downregulation of FOXO3a. Cell Death Dis. 2013 Aug1;4: e745.

    8.         WeiR, Huang GL, Zhang MY, Li BK, Zhang HZ, Shi M, Chen XQ, Huang L, Zhou QM, JiaWH, Zheng XF, Yuan YF, Wang HY.Clinical significance and prognostic value of microRNA expression signatures inhepatocellular carcinoma. Clin Cancer Res, 2013 Sep1;19(17):4780-4791. Epub 2013 Jun 28.

    9.         LeiR, Tang J, Zhuang X, Deng R, Li G, Yu J, Liang Y, Xiao J, Wang HY, Yang Q, Hu G. Suppression of MIM by microRNA-182activates RhoA and promotes breast cancer metastasis. Oncogene. 2013 Mar 11.[Epub ahead of print].

    10.     YangS, Wang H, Guo Y, Chen S, Zhang MY, Shen J, Yu H, Miao J, Wang HY (co-corresponding), Wei W. RMP Plays Distinct Roles in theProliferation of Hepatocellular Carcinoma Cells and Normal Hepatic Cells. Int JBiol Sci. 2013 Jul 5;9(6):637-48.

    11.     ZhangN, Wang X, Huo Q, Li X, Wang H,Schneider P, Hu G, Yang Q. The oncogene metadherin modulates the apoptoticpathway based on the tumor necrosis factor superfamily member TRAIL in breastcancer. J Biol Chem. 2013, 288(13):9396-407. Epub 2013 Feb 13.

    12.     LiuN, Cui RX, He QM, Huang BJ, Sun Y, Xie D, Zeng J, Wang HY (co-corresponding), Ma J. Reduced expression ofDicer11 is associated with poor prognosis in patients with nasopharyngealcarcinoma. Med Oncol. 2013 Mar; 30(1):360. doi: 10.1007/s12032-012-0360-3.Epub 2013 Jan 10.

    13.     LiuN, Tang LL, Sun Y, Cui RX, Wang HY, HuangBJ, He QM, Jiang W, Ma J. MiR-29c suppresses invasion and metastasis bytargeting TIAM1 in nasopharyngeal carcinoma. Cancer Lett. 2013 Feb 28;329(2):181-188. doi: 10.1016/j.canlet.2012.10.032. Epub 2012 Nov 8.

    14.     LiPD, Zhang WJ, Zhang MY, Yuan LJ, Cha YL, Ying XF, Wu G, Wang HY. Overexpression of RPS6KB1 predicts worse prognosisin primary HCC patients. Med Oncol. 2012 Dec;29(5):3070-6.  2012 Jun 10 [Epub ahead of print].

    15.     Rui-XueCui, Na Liu, Qing-Mei He, Wen-Fei Li, Bi-Jun Huang, Ying Sun, Ling-Long Tang,Mo Chen, Ning Jiang, Lei Chen, Jing-Ping Yun, Jing Zeng, Ying Guo, Hui-Yun Wang (co-corresponding), Jun Ma. Low BRMS1 expressionpromotes nasopharyngeal carcinoma metastasis in vitro and in vivo and isassociated with poor patient survival. BMC Cancer, 2012 Aug 29;12(1):376.doi: 10.1186/1471-2407-12-376.

    16.     Guo-LiangHuang, Bin-Kui Li, Mei-Yin Zhang, Rong-Rong Wei, Yun-Fei Yuan, Ming Shi,Xiao-Qian Chen, Long Huang, Hui-Zhong Zhang, Wanqing Liu, Bi-Jun Huang, HonghuaLi, Xiao-Feng Zheng, Xian-Rong Luo, Hui-YunWang . Allele loss and down-regulation of heparanase gene areassociated with progression and poor prognosis of hepatocellular carcinoma. PlosOne, 2012;7(8):e44061. doi:10.1371/journal.pone.0044061. Epub 2012 Aug 31.

    17.     Shajo Kunnath-Velayudhan, AmyL. Davidow, Hui-Yun Wang,Douglas M. Molina, Vu T. Huynh, Hugh Salamon, Richard Pine, Gerd Michel, MarkD. Perkins, Liang Xiaowu, Philip L. Felgner, JoAnne L. Flynn, AntoninoCatanzaro, Maria L. Gennaro. Proteome-ScaleAntibody Responses and Outcome of Mycobacterium tuberculosis Infection inNonhuman Primates and in Tuberculosis Patients. J Infect Dis. 2012Sep;206(5):697-705.

    18.     Na Liu, Nian-Yong Chen, Rui-XueCui, Wen-Fei Li,  Yan Li,Rong-Rong Wei,  Mei-Ying Zhang, Bi-JunHuang, M.S., Ying Sun, Ling-Long Tang, Mo Chen, Guang-Qun Zhou,Qing-Mei He, Ning Jiang, Lei Chen, Jing-Ping Yun, Jing Zen,  Li-Zhi Liu, Li Li, Ying Guo, Hui-Yun Wang (co-corresponding) and Jun Ma. Prognosticvalue of a microRNA signature in nasopharyngeal carcinoma: a microRNAexpression analysis. Lancet Oncology, 2012, Jun; 13(6):633-41.  Epub2012 May 3.

    19.     LongHuang, Jia-Xin Lin, Yan-Hong Yu, Mei-Yin Zhang, Hui-Yun Wang (co-corresponding), Min Zheng. Downregulation of Six MicroRNAs IsAssociated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis inSmall Cell Carcinoma of the Cervix. PLoS ONE, 2012;7(3):e33762. Epub2012 Mar 16.

    20.     YiC, Wang Q, Wang L, Huang Y, Li L, Liu L, Zhou X, Xie G, Kang T, Wang H, Zeng M, Ma J, Zeng Y,Yun JP. MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes theproliferation and tumorigenesis of nasopharyngeal carcinoma. Oncogene.2012 Oct 11; 31(41):4421-33 . doi: 10.1038/onc.2011.629. [Epub ahead of print]

    21.     LongHuang, Min Zheng, Mei-Yin Zhang, Qing-Ming Zhou, Yin Zhang, Wei-Hua Jia and Hui-Yun Wang. A Gene ExpressionSignature Predicts the Prognosis of Patients with Cervical Carcinoma. MedOncol. 2012 Dec;29(4):2911-8.

    22.     Rong-RongWei, Mei-Yin Zhang, Hui-Lan Rao, Heng-Yin Pu, Hui-Zhong Zhang, Hui-Yun Wang . Identification ofADH4 as a novel and potential prognostic marker in hepatocellular carcinoma. MedOncol. 2012 Dec;29(4):2737-43. doi: 10.1007/s12032-011-0126-3. Epub2011 Dec 7.

    23.     ChenXQ, He JR, Wang HY. Decreasedexpression of ALDH1L1 is associated with a poor prognosis in hepatocellularcarcinoma. Med Oncol. 2012 Sep; 29(3):1843-9. Epub 2011 Oct 11.

    24.     LongHuang, Min Zheng, Qing-Min Zhou, Mei-Ying Zhang, Wei-Hua Jia, Jing-Ping Yun and Hui-Yun Wang. Identification of a gene-expression signature forpredicting lymph node metastasis in early stage patients with cervicalcarcinoma. Cancer, 2011 Aug1;117(15):3363-73. 

    25.     Pramanik S, Cui X, Wang HY,Chimge NO, Hu G, Shen L, Gao R, Li H. Segmental duplication as one of thedriving forces underlying the diversity of the human immunoglobulin heavy chainvariable gene region. BMC Genomics.2011, 12(1):78.

    26.     Kunnath-VelayudhanS*, Salamon H*, Wang HY*(Co-firstAuthor),Davidow AL, Molina DM, Huynh VT, Cirillo DM, Michel G, Talbot EA, Perkins MD,Felgner PL, Liang X, Gennaro ML. Dynamic antibody responses to theMycobacterium tuberculosis proteome. ProcNatl Acad Sci USA. 2010 Aug 17;107(33):14703-8.

    27.     HaiqingMa, Desheng Weng, Yibing Chen, Wei Huang, Ke Pan, Hui Wang, Jiancong Sun,Qijing Wang, Zhiwei Zhou, Huiyun Wang* (Co-corresponding author) and Jianchuan Xia*. Extensive analysis of D7S486 in primary gastric cancersupports TESTIN as a candidate tumor suppressor gene. Mol Cancer.2010, 9:190.         

    28.     Guo-Liang Huang, Bin-Kui Li,Mei-Yin Zhang, Hui-Zhong Zhang, Rong-Rong Wei, Yun-Fei Yuan, Ming Shi,Xiao-Qian Chen, Long Huang, An-Hua Li, Bi-Jun Huang, Honghua Li, Hui-YunWang. LOH analysis of genes around D4S2964 identifies ARD1B as aprognostic predictor of hepatocellular carcinoma. World Journal of Gastroenterology, 2010, 16(16):2046-2054.

    29.     HuakunZhang, Haiqing Ma, Qijing Wang, Minshan Chen, Desheng Weng, Hui Wang, Jun Zhou,Yongqiang Li, Jiancong Sun, Yibing Chen, Xiaoting Liang, Jingjing Zhao, Ke Pan, Huiyun Wang (Co-corresponding),Jianchuan Xia. Analysis of loss of heterozygosity on chromosome 4q inhepatocellular carcinoma using high-throughput SNP array. Oncol Rep,2010,23(2): 445-455.

    30.     Hui-Yun Wang, Danielle Greenawalt, Xiangfeng Cui, Irina Tereshchenko, MinjieLuo, Qifeng Yang, Marco Azaro, Guohong Hu, Yi Chu, James Y. Li, Li Shen, YongLin, Lianjun Zhangand Honghua Li. Identification of Possible Genetic Alterations in the Breast Cancer CellLine MCF-7 Using High-density SNP Genotyping Microarray. Journal of Carcinogenesis, 2009, 8:6.

    31.     Minjie Luo, Xiangfeng Cui,David Fredman, Anthony J. Brookes, Marco A. Azaro, Danielle M.Greenawalt,Guohong Hu, Hui-Yun Wang, Irina V. Tereshchenko1, Yong Lin, YueShentu, Richeng Gao, Li Shen, Honghua Li. Genetic structures of copy number variants revealed by genotyping singlesperm.  PLoS ONE. 2009,4(4):e5236.

    32.     Guohong Hu, Qifeng Yang,Xiangfeng Cui, Gang Yue, Marco Azaro, Hui-Yun Wang and HonghuaLi. A Highly Sensitive and Specific System forLarge-scale Gene Expression Profiling.  BMC Genomics, 2008, 9(1): 9.

    33.     Marc Q. Ma, Kai Zhang, Hui-YunWang and Frank Y. Shi.  ELBELB-Q, A New Method for Improving the Robustness in DNA Microarray ImageQuantification.  IEEE Transactionson Information Technology in Biomedicine, 2007,11(5): 574-582.

    34.     Guohong Hu, Hui-Yun Wang,Danielle M. Frikker, Marco A. Azaro, Minjie Luo, Irina V. Tereshchenko,Xiangfeng Cui, Qifeng Yang, Richeng Gao, Li Shen, and Honghua Li. AccuTyping:New Algorithms for Large-scale SNPs Genotyping in Two-color Microarray. NucleicAcids Research, 2006, 34(17):e116.

    35.     Danielle M. Greenawalt, XiangfengCui, Yujun Wu, Yong Lin, Hui-Yun Wang, Minjie Luo, Irina V.Tereshchenko, Guohong Hu, James Y. Li, Yi Chu, Marco A. Azaro, CristinaDeCoste, Nyam-Osor Chimge, Richeng Gao, Li shen, Weichung J. Shih, KennethLange, and Honghua Li.  Strong Correlationbetween Meiotic Crossovers and the Haplotype Structure on the Long Arm ofChromosome 21.  Genome Research, 2006 16: 208-214.

    36.     Hui-Yun Wang, Mijie Luo, Irina Tereshchenko, Danielle Frikker, Xiangfeng Cui,James Y. Li, Guohong Hu, Yi Chu, Marco Azaro, Li shen, Qifeng Yang, ManousosKambouris, Richeng Gao, and Honghua Li. A Genotyping System Capable of Simultaneously Analyzing >1,000 SingleNucleotide Polymorphisms in a Haploid Genome.  Genome Research 2005, 15(2): 276-283.

    37.     Feng BJ, Huang W, Shugart YY,Lee MK, Zhang F, Xia JC, Wang HY, Huang TB, Jian SW, Huang P,Feng QS, Huang LX, Yu XJ, Li D, Chen LZ, Jia WH, Fang Y, Huang HM, Zhu JL, LiuXM, Zhao Y, Liu WQ, Deng MQ, Hu WH, Wu SX, Mo HY, Hong MF, King MC, Chen Z,Zeng YXGenome-wide scan forfamilial nasopharyngeal carcinoma and evidence for linkage to chromosome4.  Nature Genetics, 2002;31(4): 395-399.

    38.     Shao JY, Huang XM, Yu XJ, HuangLX, Wu QL, Xia JC, Wang HY, Feng QS, Ren ZF, Ernberg I, Hu LF,Zeng YX.  Loss of heterozygosity and itscorrelation with clinical outcome and Epstein-Barr virus infection innasopharyngeal carcinoma.  AnticancerResearch, 2001; 21 (4B): 3021-3029.

    39.     Li SP, Wang HY (co-firstauthor), Zhang Chang-Qing, Feng Qi-Sheng, Huang Ping, Yu Xing-Juan,Huang Li-Xi, Liang Qi-Wang and Zeng Yi-Xin. Genome-wide analyses on loss of heterozygosity in hepatocellularcarcinoma in Southern China.  Journalof Hepatology, 2001; 34(6): 840-849.

    40.     Shao Jian-Yong, WangHui-Yun(co-first author), Huang Xiao-Ming, Feng Qi-Sheng,Huang Ping, Feng Bing-Jian, Huang Li-Xi, Yu Xing-Juan, Hu Li-Fu, Ernberg I andZeng Yi-Xin.  Genome-wide allelotypeanalysis of sporadic primary nasopharyngeal carcinoma from southern China.  International Journal of Oncology, 2000; 17(6): 1267-1275.


    Last updated on: August, 2014


    Jia Weihua
    Title Professor, Doctoral advisor

    Professor Wei-hua Jia obtained her PhD in Medicine in Epidemiology from Peking Union Medical College. After her PhD training, she joined the Department of Experimental Research at Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China. Prof. Jia has long been dedicated to research on cancer epidemiology, cancer genetics and genomics, especially on the interactive effects among Epstein Barr virus (EBV), genetics and the environment in nasopharynx carcinoma. She has published more than 150 SCI papers in world renowned journals such as Nature Genetics, J Natl Cancer I and Am J Human Genet. She has investigated the long-term trend and risk factors of nasopharynx carcinoma in high-incidence areas. She first reported a relationship between smoking and reactivation of EBV and proposed its potential etiological role for nasopharynx carcinoma. Besides, she has discovered new susceptible genes of nasopharynx carcinoma, including DNA repair genes, metabolism genes for exogenous compounds and series of genes related to immune response, and established a predictive model for onset risk of nasopharynx carcinoma. Her other research interests include discovering new susceptible genes of colorectal cancer and lymphoma, and identifying the genomic characteristics that contribute to the tumorigenesis and prognosis of multiple cancers. She was awarded the National Ten-thousand Talents in Scientific and Technological Innovation (2016), and the National Science Fund for Distinguished Young Scholars (2013). At present, she is Vice-chair of Chinese Anti-Cancer Association Cancer Epidemiology Professional Committee, Vice-chair of the Tissue Biological Samples Branch for Chinese Medicine Biotechnology Association, Chair of Guangdong Anti-Cancer Association Cancer Epidemiology Professional Committee.

    Research Interest(s)

    Molecular epidemiology of Cancer

    Cancer genetics and genomics

    Cancer risk prediction and individual intervention


    1995.09 - 1998.07  Doctor of medicine in epidemiology, Peking Union Medical College

    1995.07 - 1992.09  Master of medicine in epidemiology, Peking Union Medical College

    1992.07 - 1987.09  Bachelor of preventive medicine, Shanxi Medical University


    Selected publications

    [1] Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population. Tan DE, Foo JN, Bei JX, Chang J, Peng R, Zheng X, Wei L, Huang Y, Lim WY, Li J, Cui Q, Chew SH, Ebstein RP, Kuperan P, Lim ST, Tao M, Tan SH, Wong A, Wong GC,Tan SY, Ng SB, Zeng YX, Khor CC, Lin D*, Seow AL*, Jia WH*, Liu J*. Nat Genet. 2013 Jul;45(7):804-7.

    [2] Genome-wide association analyses in east Asians identify new susceptibility loci for colorectal cancer. Jia WH#, Zhang B#, Matsuo K, Shin A, Xiang YB, Jee SH, Kim DH, Ren Z, Cai Q, Long J, Shi J, Wen W, Yang G, Delahanty RJ; Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO); Colon Cancer Family Registry (CCFR), Ji BT, Pan ZZ, Matsuda F, Gao YT, Oh JH, Ahn YO, Park EJ, Li HL, Park JW, Jo J, Jeong JY, Hosono S, Casey G, Peters U, Shu XO, Zeng YX, Zheng W. Nat Genet. 2013 Feb;45(2):191-6.

    [3] Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. Dai J, Lv J, Zhu M, Wang Y, Qin N, Ma H, He YQ, Zhang R, Tan W, Fan J, Wang T, Zheng H, Sun Q, Wang L, Huang M, Ge Z, Yu C, Guo Y, Wang TM, Wang J, Xu L, Wu W, Chen L, Bian Z, Walters R, Millwood IY, Li XZ, Wang X, Hung RJ, Christiani DC, Chen H, Wang M, Wang C, Jiang Y, Chen K, Chen Z, Jin G, Wu T, Lin D, Hu Z*, Amos CI*, Wu C*, Wei Q*, Jia WH*, Li L*, Shen H*. Lancet Respir Med 2019;7:881-91

    [4] Genome-Wide Association Study of Susceptibility Loci for Radiation-Induced Brain Injury. Wang TM, Shen GP, Chen MY, Zhang JB, Sun Y, He J, Xue WQ, Li XZ, Huang SY, Zheng XH, Zhang SD, Hu YZ, Qin HD, Bei JX, Ma J, Mu J, Yao Shugart Y, Jia WH*.J Natl Cancer Inst. 2018 Oct 8.

    [5] An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and epstein-barr virus activation. Xu FH, Xiong D,Xu YF, Cao SM, Xue WQ, Qin HD, Liu WS, Cao JY, Zhang Y, Feng QS, Chen LZ, Li MZ, Liu ZW, Liu Q, Hong MH, Shugart YY, Zeng YX , Zeng MS*, Jia WH*. J Natl Cancer Inst. 2012 Sep 19;104(18):1396-410.

    [6] Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women. Chen K* ,Ma H ,Li L ,Zang R , Wang C , Song F ,Shi T ,Yu D,Yang M,Xue W,Dai J, Li S, Zheng H, Wu C, Zhang Y, Wu X,Li D, Xue F,Li H, Jiang Z, Liu J, Liu Y, Li P, Tan W, Han J, Jie J, Hao Q, Hu Z, Lin D, Ma D*,Jia W*,Shen H*,Wei Q*. Nat Commun. 2014 Aug 19;5:4682.

    [7] Genomic Characterization of Esophageal Squamous Cell Carcinoma Reveals Critical Genes Underlying Tumorigenesis and Poor Prognosis. Qin HD, Liao XY, Chen YB, Huang SY, Xue WQ, Li FF, Ge XS, Liu DQ, Cai Q, Long J, Li XZ, Hu YZ, Zhang SD, Zhang LJ, Lehrman B, Scott AF, Lin D, Zeng YX, Shugart YY*, Jia WH*. Am J Hum Genet. 2016 Apr 7;98(4):709-27.

    [8] Non-viral environmental risk factors for nasopharyngeal carcinoma: A systematic review. Jia WH*, Qin HD. Semin Cancer Biol. 2012 Apr;22(2):117-26.

    [9] Comprehensive Pathway-Based Association Study of DNA Repair Gene Variants and the Risk of Nasopharyngeal Carcinoma. Qin HD, Shugart YY, Bei JX, Pan QH, Chen L, Feng QS, Chen LZ, Huang W, Liu JJ, Jorgensen TJ, Zeng YX, Jia WH*. Cancer Res. 2011, 71(8):3000-8.

    [10] Global trends in incidence and mortality of nasopharyngeal carcinoma. Tang LL, Chen WQ, Xue WQ, He YQ, Zheng RS, Zeng YX, Jia WH*.Cancer Lett 2016;374: 22-30.

    [11] The Relationship Between Environmental Factors and the Profile of Epstein-Barr Virus Antibodies in the Lytic and Latent Infection Periods in Healthy Populations from Endemic and Non-Endemic Nasopharyngeal Carcinoma Areas in China. He YQ, Xue WQ, Xu FH, Xu YF,  Zhang JB, Yu HL, Feng QS, Chen LZ, Cao SM, Liu Q, Mu JB, Zeng YX, Jia WH*. EBiomedicine 2018 (30): 184-191.

    [12] Natural Variations in BRLF1 Promoter Contribute to the Elevated Reactivation Level of Epstein-Barr Virus in Endemic Areas of Nasopharyngeal Carcinoma. Zhang JB, Huang SY, Wang TM, Dong SQ, He YQ, Zheng XH,Li XZ, Wang F, Mu JB, Jia WH*. EBioMedicine. 2018 Nov 9.

    [13] Association Between Environmental Factors and Oral Epstein-Barr Virus DNA Loads: A Multicenter Cross-sectional Study in China.  He YQ, Liao XY, Xue WQ, Xu YF, Xu FH, Li FF, Li XZ, Zhang JB, Wang TM, Wang F, Yu HL, Feng QS, Chen LZ, Cao SM, Liu Q, Mu J, Jia WH*. J Infect Dis. 2018 Oct 11.

    [14] Human genetic variants of homologous recombination repair genes first found to be associated with Epstein-Barr virus antibody titers in healthy Cantonese. Shen GP, Pan QH, Hong MH, Qin HD, Xu YF, Chen LZ, Feng QS, Jorgensen TJ, Shugart YY, Zeng YX, Jia WH*. Int J Cancer. 2011 Sep 15;129(6):1459-66.

    Updated May 2020

    Xin-Yuan Guan
    Title Professor

    Prof. Xin-Yuan Guan got his PhD degree in 1993 at the University of Arizona. After postdoctoral training at the University of Michigan, he was recruited by National Human Genome Research Institute in NIH as a senior staff fellow in 1993. He was then moved to the Department of Clinical Oncology, The University of Hong Kong in 1999 as an Associate Professor, and promoted to Professor in 2007. He is Professor of Sun Yat-sen University Cancer Center since 2007.

    His major scientific contributions include:
    (1) development and application of Micro-FISH technique in cancer research;

    (2) identification and characterization of novel oncogenes, such as EIF5A2 and CHD1L in various cancers;

    (3) identification and characterization of cancer stem cells in hepatocellular and esophageal carcinomas.

    Currently, Prof. Guan’s research interests include cancer stem cell, cancer microenvironment, and cancer related genes in liver, esophageal and nasopharyngeal cancers. He has published more than 270 peer-reviewed papers in international journals including in Science, Nature Genetics, Nature Medicine, Cell Stem Cell, J Clin Invest, Gastroenterology, Hepatology, Gut, Cancer Research, and Oncogene.
    Research Interest(s): Characterization of cancer related genes, cancer stem cells and tumor microenvironment in hepatocellular, esophageal and nasopharyngeal carcinomas.

    Research Interest(s)

    Characterization of cancer related genes, cancer stem cells and tumor microenvironment in hepatocellular, esophageal and nasopharyngeal carcinomas.

    For information on Professor Guan's laboratory, click here and select: Characterization of cancer-related genes.

    Education Ph.D., Department of Genetics, University of Arizona, USA, 1993.

    Selected publications

    1. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, Ng I, Man K, Wong N, To KF, Zheng BJ, Lai PB, Lo CM, Chan KW, Guan XY*. miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010

    2. Ma S, Bao YJ, Kwan PS, Chan YP, Tong CM, Fu L, Zhang N, Tong AH Qin YR, Tsao SW, Chan KW, Lok S, Guan XY*. Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma. Gastroenterology 2012

    3. Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, Liu M, Yuan YF, Fu L, Kong KL, Qi L, Li Y, Zhang N, Tong AH, Kwong DL, Man K, Lo CM, Lok S, Tenen DG, Guan XY*. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med 2013

    4. Liu M, Li Y, Chen L, Chan TH, Song Y, Fu L, Zeng TT, Dai YD, Zhu YH, Li Y, Chen J, Yuan YF, Guan XY*. Allele-specific imbalance of oxidative stress-induced growth inhibitor 1 associates with progression of hepatocellular carcinoma. Gastroenterology 2014

    5. Song Y, Pan G, Chen L, Ma S, Zeng T, Chan TH, Li L, Lian Q, Chow R, Cai X, Li Y, Li Y, Liu M, Li Y, Zhu Y, Wong N, Yuan YF, Pei D, Guan XY*. Loss of ATOH8 increases stem cell features of hepatocellular carcinoma cells. Gastroenterology 2015

    6. Ming XY, Fu L, Zhang LY, Qin YR, Cao TT, Chan KW, Ma S, Xie D, Guan XY*. Integrin α7 is a functional cancer stem cell surface markerin oesophageal squamous cell carcinoma. Nat Commun 2016

    7. Fu L, Qin YR, Ming XY, Zuo XB, Diao YW, Zhang LY, Ai J, Liu BL, Huang TX, Cao TT, Tan BB, Xiang D, Zeng CM, Gong J, Zhang Q, Dong SS, Chen J, Liu H, Wu JL, Qi RZ, Xie D, Wang LD, Guan XY*. RNA editing of SLC22A3 drives early tumor invasion and metastasis in familial esophageal cancer. Pro Nat Aca Sci USA 2017

    8. Jiang L, Yan Q, Fang S, Liu M, Li Y, Yuan YF, Li Y, Zhu Y, Qi J, Yang X, Kwong DLW, Guan XY*. Calcium binding protein 39 promotes hepatocellular carcinoma growth and metastasis by activating ERK signaling pathway. Hepatology 2017

    9. Li L, Li JC, Yang H, Zhang X, Liu LL, Li Y, Zeng TT, Zhu YH, Li XD, Li Y, Xie D, Fu L, Guan XY*. Expansion of cancer stem cell pool initiates lung cancer recurrence before angiogenesis. Proc Natl Acad Sci USA 2018

    10. Liu M, Yan Q, Sun Y, Nam Y, Hu L, Loong JHC, Ouyang Q, Zhang Y, Li HL, Kong FE, Li L, Li Y, Li MM, Cheng W, Jiang LX, Fang S, Yang XD, Mo JQ, Gong YF, Tang YQ, Li Y, Yuan YF, Ma NF, Lin G, Ma S, Wang JG, Guan XY*. A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets. Pro Nat Aca Sci USA 2020

    Updated May 2020

    Zheng Limin
    Title Professor

    Limin Zheng graduated from Shanghai Medical University in 1984 and then worked as a physician in Hua-Shan University Hospital. He obtained his PhD in Leiden University, The Netherlands, in 1994 and was promoted as Assistant Professor by Swedish Medical Research Council in 1998. Since 2003, he is full Professor at Sun Yat-sen University. He received the Outstanding Young Scientist Fund from National Natural Science Fund of China in 2004 and the honors as Cheung Kong Scholars by Ministry of Education in 2009. He received the National Award for Medical Research in 2014 and is included on the list of Most Cited Chinese Researchers (based on the Scopus database from Elsevier) for eight consecutive years since 2015.

    Research Interest(s)

    Tumor Immunology, with focus on Myeloid cells in human tumor microenvironments; Macrophage Biology, Liver Cancer, and Tumor Immune Staging/Immunotherapy

    The main research activities from Dr. Zheng’s Lab are to delineate the dynamic interactions between the malignant and immune cells (focused on the myeloid cells, including monocytes/macrophages, MDSC and neutrophils) in human solid tumors. We are also interested in the altered origin and functional activities of these myeloid cells in tumor-bearing hosts, which could serve as novel strategy for effective anti-tumor therapy.  


    1979 – 1984 MD. Shanghai Medical University (SMU), China

    1984 – 1990 Resident, Hua-Shan Hospital, SMU, China

    1990 – 1994 PhD, Leiden University, The Netherlands

    1994 – 1998 Postdoctoral Fellow, Lund and Linkoping University, Sweden


    Selected publications

    (1) Liu M*, Wu C*, Luo S, Hua Q, Chen HT, Weng Y, Xu J, Lin H, Wang L, Li J, Zhu L, Guo Z, Zhuang SM, Kang T, Zheng L#. PERK reprograms hematopoietic progenitor cells to direct tumor-promoting myelopoiesis in the spleen. J Exp Med. 2022 Apr 4;219(4):e20211498.

    (2) Ning WR, Jiang D, Liu XC, Huang YF, Peng ZP, Jiang ZZ, Kang T, Zhuang SM, Wu Y#, Zheng L#. Carbonic anhydrase XII mediates the survival and prometastatic functions of macrophages in human hepatocellular carcinoma. J Clin Invest. 2022 Apr 1;132(7):e153110.

    (3) Chen J*, Sun HW*, Yang YY, Chen HT, Yu XJ, Wu WC, Xu YT, Jin LL, Wu XJ, Xu J#, Zheng L#. Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer. Signal Transduct Target Ther. 2021 Jan 8;6(1):447-460.

    (4) Wang J*, Wang Y*, Chu Y, Li Z, Yu X, Huang Z, Xu J, Zheng L#. Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma. J Hepatol. 2021 Mar;74(3):627-637.

    (5) Sun HW*, Chen J*, Wu WC, Yang YY, Xu YT, Yu XJ, Chen HT, Wang Z, Wu XJ, Zheng L#. Retinoic Acid Synthesis Deficiency Fosters the Generation of Polymorphonuclear Myeloid-Derived Suppressor Cells in Colorectal Cancer. Cancer Immunol Res. 2021 Jan;9(1):20-33.

    (6) Wu C*, Lin J*, Weng Y, Zeng DN, Xu J, Luo S, Xu L, Liu M, Hua Q, Liu CQ, Li JQ, Liao J, Sun C, Zhou J, Chen MS, Liu C, Guo Z, Zhuang SM, Huang JH, Zheng L#. Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. J Clin Invest. 2020 Sep 1;130(9):4679-4693.

    (7) Xiao G*, Jin LL*, Liu CQ, Wang YC, Meng YM, Zhou ZG, Chen J, Yu XJ, Zhang YJ, Xu J#, Zheng L#. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. J Immunother Cancer. 2019 Nov 14;7(1):300.

    (8) Wu WC*, Sun HW*, Chen J, OuYang HY, Yu XJ, Chen HT, Shuang ZY, Shi M, Wang Z, Zheng L#. Immunosuppressive Immature Myeloid Cell Generation Is Controlled by Glutamine Metabolism in Human Cancer. Cancer Immunol Res. 2019 Oct;7(10):1605-1618.

    (9) Wu C, Ning H, Liu M, Lin J, Luo S, Zhu W, Xu J, Wu WC, Liang J, Shao CK, Ren J, Wei B, Cui J, Chen MS, Zheng L#. Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. J Clin Invest. 2018 Aug 1;128(8):3425-3438.

    (10) Chen DP, Ning WR, Li XF, Wei Y, Lao XM, Wang JC, Wu Y, Zheng L#. Peritumoral monocytes induce cancer cell autophagy to facilitate the progression of human hepatocellular carcinoma. Autophagy. 2018; 14:1335-1346. 

    Updated June 2022

    Yan Li
    Title Professor

    Dr. Yan Li obtained her M.D. degree at Hubei University of Medicine and Ph.D degree at Sun Yat-sen Medical University in 1995 and 2001, respectively. She had post-doctoral training in School of Medicine, Yale University from 2004-2005. Dr. Yan Li has acquired many funds from NSFC (82072604, 81871903, 81672357, 81472255, 81172338 and 30700820) and Guangdong Province. She was awarded as Outstanding Young Medical Talents in Guangdong Province in 2018. She has published more than 70 peer-reviewed papers, including Gastroenterology, Cancer Research and Oncogene.

    Research Interest(s)

    Dr. Yan Li is interested in molecular mechanism of tumorigenesis, metastasis and interactions between microenvironment and tumor cell. She has identified some tumor suppressors, oncogenes and non-coding RNAs in ESCC and HCC. She also found a novel mechanism of genomic instability in esophageal cancers.


    M.D. School of Medicine, Hubei University of Medicine, China 1990-1995

    Ph.D. Sun Yat-sen Medical University, China 1996-2001


    1. Suo D, Wang Z, Li L, Chen Q, Zeng T, Liu R, Yun J, Guan XY*, Li Y*. HOXC10 upregulation confers resistance to chemoradiotherapy in ESCC tumor cells and predicts poor prognosis. Oncogene  2020

    2. Suo D#, Wang L#, Zeng T, Zhang H, Li L, Liu J, Yun J, Guan XY*, Li Y*. NRIP3 upregulation confers resistance to chemoradiotherapy in ESCC via RTF2 removal by accelerating ubiquitination and degradation of RTF2. Oncogenesis 2020 

    3. Zeng T#, Tang Z#, Liang L, Suo D, Li L, Li J, Yuan Y, Guan XY*, Li Y*. PDSS2-Del2, a new variant of PDSS2, promotes tumor cell metastasis and angiogenesis in hepatocellular carcinoma via activating NF-κB. Mol Oncol 2020 

    4. Zhan YT#, Li L#, Zeng TT, Zhou NN, Guan XY*, Li Y*. SNRPB-mediated RNA splicing drives tumor cell proliferation and stemness in hepatocellular carcinoma. Aging (Albany NY)  2020 

    5. Zheng YL#, Li L#, Jia YX, Zhang BZ, Li JC, Zhu YH, Li MQ, He JZ, Zeng TT, Ban XJ, Yuan YF, Li Y*, Guan XY*. LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway. Theranostics 2019 

    6. Li M, Wang L, Zhan Y, Zeng T, Zhang X, Guan XY*, Li Y*. Membrane Metalloendopeptidase (MME) Suppresses Metastasis of Esophageal Squamous Cell Carcinoma (ESCC) by Inhibiting FAK-RhoA Signaling Axis. Am J Pathol 2019 

    7. Li Y*, Lin S, Li L, Tang Z, Hu Y, Ban X, Zeng T, Zhou Y, Zhu YH, Gao S, Deng W, Zhang X, Xie D, Yuan Y, Huang P, Li J, Cai Z, Guan XY*. PDSS2 deficiency induces hepatocarcinogenesis by decreasing mitochondrial respiration and reprogramming glucose metabolism. Cancer Res 2018 

    8. Zhang B, Zhang Z, Li L, Qin YR, Liu H, Jiang C, Zeng TT, Li MQ, Xie D, Li Y*, Guan XY*, Zhu YH*. TSPAN15 interacts with BTRC to promote oesophageal squamous cell carcinoma metastasis via activating NF-κB signaling. Nat Commun 2018  

    9. Zhou Y, Wang L, Ban X, Zeng T, Zhu Y, Li M, Guan XY*, Li Y*. DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma. Oncogene 2018

    10. Wang L, Li M, Zhan Y, Ban X, Zeng T, Zhu Y, Yun J, Guan XY*, Li Y*. Down-regulation of POTEG predicts poor prognosis in esophageal squamous cell carcinoma patients. Mol Carcinog 2018 

    11. Huang PY, Zeng TT, Ban X, Li MQ, Zhang BZ, Zhu YH, Hua WF, Mai HQ, Zhang L, Guan XY*, Li Y*. Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy. BMC Cancer 2016 

    12. Yang H, Li XD, Zhou Y, Ban X, Zeng TT, Li L, Zhang BZ, Yun J, Xie D, Guan XY, Li Y*. Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma. Oncotarget 2015 

    13. Li H, Zhang J, Chen SW, Liu LL, Li L, Gao F, Zhuang SM, Wang LP, Li Y*, Song M*. Cancer-associated fibroblasts provide a suitable microenvironment for tumor development and progression in oral tongue squamous cancer. J Transl Med 2015

    14. Huang PY, Zeng TT, Li MQ, Ban X, Zhu YH, Zhang BZ, Mai HQ, Zhang L, Guan XY*, Li Y*. Proteomic analysis of a nasopharyngeal carcinoma cell line and a nasopharyngeal epithelial cell line. Tumori 2015 

    15. Huang PY#, Li Y#, Luo DH, Hou X, Zeng TT, Li MQ, Mai HQ, Zhang L. Expression of Aurora-B and FOXM1 predict poor survival in patients with nasopharyngeal carcinoma. Strahlenther Onkol 2015 

    16. Li Y*, Fu L, Li JB, Qin Y, Zeng TT, Zhou J, Zeng ZL, Chen J, Cao TT, Ban X, Qian C, Cai Z, Xie D, Huang P, Guan XY*. Increased Expression of EIF5A2, via Hypoxia or Gene Amplification, Contributes to Metastasis and Angiogenesis of Esophageal Squamous Cell Carcinoma. Gastroenterology 2014 

    17. Song Y, Li J, Zhu Y, Dai Y, Zeng T, Liu L, Li J, Wang H, Qin Y, Zeng M, Guan XY*, Li Y*. MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma. Oncotarget 2014 

    18. Li Y*, Zhu CL, Nie CJ, Li JC, Zeng TT, Zhou J, Chen J, Chen K, Fu L, Liu H, Qin Y, Guan XY*.  Investigation of Tumor Suppressing Function of CACNA2D3 in Esophageal Squamous Cell Carcinoma. PLoS One 2013

    19. Chen K, Li Y*, Dai Y, Li J, Qin Y, Zhu Y, Zeng T, Ban X, Fu L, Guan XY*. Characterization of Tumor Suppressive Function of cornulin in Esophageal Squamous Cell Carcinoma. PLoS One 2013 

    20. Huang PY#, Li Y#, Mai HQ, Luo RZ, Cai YC, Zhang L. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. Oral Oncol 2012 

    21. Li Y, Chen L, Nie CJ, Zeng TT, Liu H, Mao X, Qin Y, Zhu YH, Fu L, Guan XY. Downregulation of RBMS3 is associated with poor prognosis in esophageal squamous cell carcinoma. Cancer Res 2011   

    22. Li Y, Nie CJ, Hu L, Qin YR, Liu HB, Zeng TT, Chen LL, Fu L, Deng W, Chen SP, Jia WH, Zhang CY, Xie D, Guan XY.  Characterization of a novel mechanism of genomic instability involving SEI1/SET/NM23H1 pathway in esophageal cancers.  Cancer Res  2010 

    23. Li Y, Shao JY, Liu RY, Zhou L, Chai LP, Li HL, Han HY, Huang BJ, Zeng MS, Zhu XF, Liu Q, Fu LW, Huang W. Evaluation of long-term toxicity of Ad/hIFN-, an Adenoviral vector encoding the human interferon-gamma gene, in nonhuman primates. Hum Gene Ther 2008 

    24. Xue G#, Liu RY#, Li Y#, Cheng Y, Liang ZH, Wu JX, Zeng MS, Tian FZ, Huang W. Dendritic cells modified with 6Ckine/IFNgamma fusion gene induce specific cytotoxic T lymphocytes in vitro. Cancer Immunol Immunother 2007 

    Updated March 2021

    Na Liu
    Title Professor

    Dr. Na Liu is currently a Professor in the Department of Experiment Research at Sun Yat-sen University Cancer Center. She obtained her M.D. of Oncology at University of South China in 2007 and Ph.D. of Oncology at Sun Yat-sen University in 2013. She joined Sun Yat-sen University Cancer Center as an Associate Professor in November 2013. Dr. Liu’s research is focused on the molecular mechanisms of individualized treatment for nasopharyngeal carcinoma. She has published more than 30 peer-reviewed papers, including some papers in renowned journals such as Lancet Oncology, Annals of Oncology, Nature Communications, Clinical Cancer Research, Cancer Research, Cell Death and Differentiation.

    Research Interest(s)

    Dr. Na Liu is interested in the molecular mechanisms of individualized treatment for nasopharyngeal carcinoma (NPC). She identified a five-miRNA signature and a 13-gene panel for the prediction of NPC prognosis, and investigated the epigenetic regulatory mechanism (DNA methylation, miRNA, lncRNA and circRNA) of NPC metastasis, which providing novel biomarkers and targets for the individualized therapy for NPC patients.


    09/2009-07/2013 Ph.D. of Oncology, Sun Yat-sen University, Guangzhou, China 

    09/2006-07/2009 Master Degree of Oncology, Nan Hua University, Hengyang, China 

    09/2002-07/2007 Bachelor of Medicine, Nan Hua University, Hengyang, China


    1.  Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Tang XR, Li YQ, Liang SB, Jiang W, Liu F, Ge WX, Tang LL, Mao YP, He QM, Yang XJ, Zhang Y, Wen X, Zhang J, Wang YQ, Zhang PP, Sun Y, Yun JP, Zeng J, Li L, Liu LZ, Liu N,* Ma J.* Lancet Oncol, 2018

    2. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Wang HY, Ma J. Lancet Oncol, 2012

    3. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. Chen YP, Wang YQ, Lv JW, Li YQ, Chua MLK, Le QT, Lee N, Colevas AD, Seiwert T, Hayes DN, Riaz N, Vermorken JB, O'Sullivan B, He QM, Yang XJ, Tang LL, Mao YP, Sun Y, Liu N,* Ma J.* Ann Oncol, 2019

    4. HOPX hypermethylation promotes metastasis via activating SNAIL transcription and correlates with poor prognosis in NPC. Ren XY, Yang XJ, Cheng B, Chen XZ, Zhang TP, He QM, Li B, Li YQ, Tang XR, Wen X, Zhong Q, Kang TB, Zeng MS, Liu N,* Ma J.* Nat Commun, 2017

    5. Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1. Hong X,# Liu N,# Liang Y,# He Q, Yang X, Lei Y, Zhang P, Zhao Y, He S, Wang Y, Li J, Li Q, Ma J, Li Y. Mol Cancer, 2020

    6. RAB37 hypermethylation regulates metastasis and resistance to docetaxel-based induction chemotherapy in nasopharyngeal carcinoma. Li Y, Yang X, Du X, Lei Y, He Q, Hong X, Tang X, Zhang P, Sun Y, Zhang J, Wang Y, Ma J, Liu N.* Clin Cancer Res, 2018

    7. Long noncoding RNA FAM225A promotes nasopharyngeal carcinoma tumorigenesis and metastasis by acting as ceRNA to sponge miR-590-3p/ miR-1275 and upregulate ITGB3. Zheng ZQ, Li ZX, Zhou GQ, Lin L, Zhang LL, Lv JW, Huang XD, Liu RQ, Chen FP, He XJ, Kou J, Zhang J, Wen X, Li YQ, Ma J, Liu N,* Sun Y.* Cancer Res, 2019

    8. Hypermethylation of SHISA3 promotes nasopharyngeal carcinoma metastasis by reducing SGSM1 stability. Zhang J, Li YQ, Guo R, Wang YQ, Zhang PP, Tang XR, Wen X, Hong XH, Lei Y, He QM, Yang XJ, Sun Y, Ma J,* Liu N.* Cancer Res, 2019

    9. EZH2-DNMT1-mediated epigenetic silencing of miR-142-3p promotes metastasis through targeting ZEB2 in nasopharyngeal carcinoma. Li Y, He Q, Wen X, Hong X, Yang X, Tang X, Zhang P, Lei Y, Hong X, Sun Y, Zhang J, Wang Y, Ma J,* Liu N.* Cell Death Differ, 2019

    10. Long non-coding RNA DANCR stabilizes HIF-1 and promotes metastasis by interacting with NF90/NF45 complex in nasopharyngeal carcinoma. Wen X, Liu X, Mao YP, Yang XJ, Wang YQ, Zhang PP, Lei Y, Hong XH, He QM, Ma J,* Liu N,* Li YQ.* Theranostics, 2018

    Last updated on: April, 2020

    Libing Song
    Title Professor

    Dr. Song  is now the team leader of the State Key Laboratory of Oncology in South China. She has long been devoted to the research on the molecular mechanism and therapeutic targets of malignant tumors such as esophageal squamous cell carcinoma and breast cancer. She has published 133 papers in which more than 60 were published in  renowned journals such as EMBO Mol Med, J Exp Med., GUT, Nat Commun., J Clin Invest., Cell Res. with a total of 6098 citations and her H-index is 46. Her research work not only revealed the novel mechanisms of tumor development and malignant progression, but also provided significant prognostic biomarkers and therapeutic targets for the potential clinical intervention of malignancies. She has obtained 4 national invention patents  and hosted 23 national / provincial  funds, including one key project supported by the National Natural Science Foundation, one national major special project, and two "973" programs (sub-project leaders). She was selected as the Leading Talent of Guangdong Special Support Program; won the first prize of Guangdong Science and Technology Award (ranked first), the second prize of China Medical Science and Technology Award (ranked first), and the second prize of Ministry of Education Natural Science Award (ranked first), the 14th Guangdong Ding Ying Science and Technology Award.

    Research Interest(s)

    Molecular mechanism of invasion and metastasis in malignancies; tumor microenvironment; non-coding RNAs.


    2002/03 - 2004/03
    Post-doctoral, Northwestern University in the USA

    1999/09 - 2001/07
    Ph.D., Oncology, Zhongshan Medical University, Guangzhou, China.

    1994/09 - 1997/07
    M.S., Oncology, Zhongshan Medical University, Guangzhou, China.

    1992/09 - 1994/07
    B.S., Nursing, Zhongshan Medical University, Guangzhou, China.


    1. Ye L, Lin C, Wang X, Li Q, Li Y, Wang M, Zhao Z, Wu X, Shi D, Xiao Y, Ren L, Jian Y, Yang M, Ou R, Deng G, Ouyang Y, Chen X, Li J, Song L*. Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer. EMBO molecular medicine 2019; 11: e10638. (IF:10.624)

    2. Ren D, Dai Y, Yang Q, Zhang X, Guo W, Ye L, Huang S, Chen X, Lai Y, Du H, Lin C, Peng X, Song L*. Wnt5a induces and maintains prostate cancer cells dormancy in bone. The Journal of experimental medicine 2019; 216: 428-449. (IF:10.892)

    3. Liu L, Lin C, Liang W, Wu S, Liu A, Wu J, Zhang X, Ren P, Li M, Song L*. TBL1XR1 promotes lymphangiogenesis and lymphatic metastasis in esophageal squamous cell carcinoma. Gut 2015; 64: 26-36. (IF:17.94)

    4. Lin C, Liu A, Zhu J, Zhang X, Wu G, Ren P, Wu J, Li M, Li J, Song L*. miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma. Nature communications 2014; 5: 4620. (IF:11.878)

    5. Chen X, Ying Z, Lin X, Lin H, Wu J, Li M, Song L*. Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. The Journal of clinical investigation 2013; 123: 2576-2589. (IF:12.282)

    6. Huang, Li T, Wang L, Zhang L, Yan R, Li K, Xing S, Wu G, Hu L, Jia W, Lin SC, Dang CV, Song L*, Gao P, Zhang H. Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress. Cell research 2016; 26: 1112-1130. (IF:17.848)

    7. Liu A, Zhu J, Wu G, Cao L, Tan Z, Zhang S, Jiang L, Wu J, Li M, Song L*, Li J*.Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma. Molecular cancer 2017; 16: 106. (IF:10.679)

    8. Wang X, Lin C, Zhao X, Liu A, Zhu J, Li X, Song L*. Acylglycerol kinase promotes cell proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Molecular cancer 2014; 13: 106. (IF:10.679)

    9. Li , Yu CP, Zhong Y, Liu TJ, Huang QD, Zhao XH, Huang H, Tu H, Jiang S, Zhang Y, Liu JH, Song L*. Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer. Annals of oncology 2012; 23: 638-646. (IF:14.196)

    10. Liu L, Chen K, Wu J, Shi L, Hu B, Cheng S, Li M, Song L*. Downregulation of miR-452 promotes stem-like traits and tumorigenicity of gliomas. Clinical cancer research 2013; 19: 3429-3438. (IF:8.911)

    11. Song L#, Gong H, Lin C, et al. Flotillin-1 promotes tumor necrosis factor-alpha receptor signaling and activation of NF-kappaB in esophageal squamous cell carcinoma cells. Gastroenterology 2012; 143: 995-1005 e1012. (IF:19.233)

    12. Song L#, Lin C, Gong H, et al. miR-486 sustains NF-kappaB activity by disrupting multiple NF-kappaB-negative feedback loops. Cell research 2013; 23: 274-289. (IF:17.848)

    13. Sun L#, Song L#, Wan Q, et al. cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions. Cell research 2015; 25: 429-444. (IF:17.848)

    14. Song L#, Liu L, Wu Z, et al. TGF-beta induces miR-182 to sustain NF-kappaB activation in glioma subsets. The Journal of clinical investigation 2012; 122: 3563-3578. (IF:12.282)

    15. Jiang L#, Lin C#, Song L#, et al. MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-kappaB/IkappaBalpha negative feedback loop. The Journal of clinical investigation 2012; 122: 33-47. (IF:12.282)

    16. Song LB#, Li J, Liao WT, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. The Journal of clinical investigation 2009; 119: 3626-3636. (IF:12.282)

    Updated May 2020

    Ran-Yi Liu
    Title Professor

    Dr Liu is a professor of oncology and molecular medicine in Sun Yat-sen University Cancer Center. His group mainly focused on the researches in targeted therapy of malignant tumors, which have been supported by grants from the National High Technology Research and Development Program of China (1 project), the National Natural Science Foundation of China (4 projects), and other government foundations. He has published 70 research papers in the SCI jounals. The research achievements in his group on cancer gene therapy received the first prize in Natural Science Award of Ministry of Education and the first prize in Science & Technology Progress Award of Guangdong Province. An anti-angiogenic gene medicine developed in his group has almost finished its phase III clinical trial.

    Research Interest(s)
    Dr. Liu’s group is interested in the researches of targeted therapy of malignant tumors (colorectal, nasopharyngeal and urogenital cancers), and the research fields include: 1) the molecular mechanisms on drug resistance/sensitivity; 2) the molecular mechanisms of initiation, progression and metastasis of colorectal and genitourinary cancer; and 3) developing targeted therapeutics based on aforementioned research achievements.

    Postdoctoral fellowship, Indiana University School of Medicine, IN 46202, USA 2008-2009 (focused on: anticancer drug resistance/sensitivity)

    Doctor of Philosophy, Sun Yat-sen University, China 2003-2007 (Major: Experimental Oncology)

    Master of Medicine, Tongji Medical University, China 1995-1998 (Major: Biochemistry & Molecular Biology)

    Bachelor of Science, Nanjing University, China 1985-1989 (Major: Biochemistry)


    Ten Selected publications: (* corresponding authors; # co-first author)

    1. Pharmacological inhibition of BAP1 recruits HERC2 to competitively dissociate BRCA1-BARD1, suppresses DNA repair and sensitizes CRC to radiotherapy. Yue X, Liu T, Wang X, Wu W, Wen G, Yi Y, Wu J, Wang Z, W, Wu R, Meng Y, Cao Z, Le L, Qiu W, Zhang X, Li Z, Chen Y, Wan G, Bu X*, Peng Z*, Liu RY*. Acta Pharmaceutica Sinica B 2023

    2. Disulfiram enhances cisplatin cytotoxicity by forming a novel platinum chelate Pt(DDTC)3. Yuan XX, Duan YF, Luo C, Li L, Yang MJ, Liu TY, Cao ZR, Huang W, Bu X, Yue X*, Liu RY*. Biochem Pharmacol 2023

    3. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. Peng QH, Wang CH, Chen HM, Zhang RX, Pan ZZ, Lu ZH, Wang GY, Yue X, Huang W, Liu RY*. J Immunother Cancer 2021

    4. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients. Zhou QH, Han H*, Lu JB, Liu TY, Huang KB, Deng CZ, Li ZS, Chen JP, Yao K, Qin ZK, Liu ZW, Li YH, Guo SJ, Ye YL, Zhou FJ, Liu RY*. Cancer Commun (Lond). 2020

    5. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. Zhou QH, Li KW, Chen X, He HX, Peng SM, Peng SR, Wang Q, Li ZA, Tao YR, Cai WL, Liu RY*, Huang H*. J Immunother Cancer. 2020

    6. Genome-wide RNAi screening identifies RFC4 as a factor that mediates radioresistance in colorectal cancer by facilitating non-homologous end joining repair. Wang XC, Yue X*, Zhang RX, Liu TY, Pan ZZ, Yang MJ, Lu ZH, Wang ZY, Peng JH, Le LY, Wang GY, Peng QH, Meng Y, Huang W*, Liu RY*. Clin Cancer Res. 2019

    7. The Heterogeneity Between Lynch-Associated and Sporadic MMR Deficiency in Colorectal Cancers. Liu GC#, Liu RY#, Yan JP#, An X#, Jiang W, Ling YH, Chen JW, Bei JX, Zuo XY, Cai MY, Liu ZX, Zuo ZX, Liu JH, Pan ZZ, Ding PR. J Natl Cancer Inst. 2018

    8. Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines. Zhou QH, Deng CZ, Li ZS, Chen JP, Yao K, Huang KB, Liu TY, Liu ZW, Qin ZK, Zhou FJ, Huang W, Han H*, Liu RY*. Cell Death Dis. 2018

    9. BST2 confers cisplatin resistance via NF-κB signaling in nasopharyngeal cancer. Kuang CM, Fu X, Hua YJ, Shuai WD, Ye ZH, Li Y, Peng QH, Li YZ, Chen S, Qian CN, Huang W*, Liu RY*. Cell Death Dis. 2017

    10. Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma. Liu RY#, Dong Z#, Liu J, Yin JY, Zhou L, Wu X, Yang Y, Mo W, Huang W, Khoo SK, Chen J, Petillo D, Teh BT, Qian CN, Zhang JT. Oncogene 2011

    Shuai Chen
    Title Professor

    Dr. Shuai Chen is professor of Molecular Medicine in SYSUCC. Dr. Chen obtained his bachelor degree in biotechnology at Xiamen University in 2002 and Ph.D. degree in Genetics at Fudan University in 2007. From 2007 to 2011, Dr. Chen worked as a postdoc fellow at Masonic Cancer Center, University of Minnesota. Dr. Chen came back to China in 2011 and worked as associate professor at Institute of Microbiology, Chinese Academy of Sciences. Since April 2014, Dr. Chen was recruited to State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center.

    Research Interest(s)

    1. Innate immune recognition of pathogens and cancer.

    2. The regulation of innate immune signal pathways.

    3. Innate immunotherapy of cancer and infectious diseases.


    2007.12-2011.2   Postdoc fellow in Experimental Medicine
    Masonic Cancer Center, University of Minnesota, USA

    2002.9-2007.6 Ph.D. in Genetics
    School of life sciences, Fudan University, Shanghai, China

    1998.9-2002.6  Bachelor degree in Biotechnology
    School of life sciences, Xiamen University, Xiamen, China


    1) Sheng C#, Wang Z#, Yao C#, Chen HM, Kan G, Wang D, Chen H*, Chen S*. CALML6 Controls TAK1 Ubiquitination and Confers Protection Against Acute Inflammation. J Immunol. 2020 Apr 17;ji1901042.

    2) Wang Z#, Sheng C#, Yao C#, Chen H, Wang D, Chen S*. The EF-Hand Protein CALML6 Suppresses Antiviral Innate Immunity by Impairing IRF3 Dimerization. Cell Rep. 2019 Jan 29;26(5):1273-1285.

    3) Sheng C, Yao C, Wang Z, Chen H, Zhao Y, Xu D, Huang H, Huang W, Chen S*. Cyclophilin J limits inflammation through the blockage of ubiquitin chain sensing. Nat Commun. 2018 Oct 22;9(1):4381.

    4) Geng R, Tan X, Wu J, Pan Z, Yi M, Shi W, Liu R, Yao C, Wang G, Lin J, Qiu L, Huang W*, Chen S*. RNF183 promotes proliferation and metastasis of colorectal cancer cells via activation of NF-κB-IL-8 axis. Cell Death Dis. 2017 Aug 10;8(8):e2994.

    5) Geng R, Tan X, Zuo Z, Wu J, Pan Z, Shi W, Liu R, Yao C, Wang G, Lin J, Qiu L, Huang W*, Chen S*. Synthetic lethal short hairpin RNA screening reveals that ring finger protein 183 confers resistance to trametinib in colorectal cancer cells. Chin J Cancer. 2017 Jul 31;36(1):63.

    6) Chen S, Sheng C, Liu D, Yao C, Gao S, Song L, Jiang W, Li J, Huang W*. Enhancer of zeste homolog 2 is a negative regulator of mitochondria-mediated innate immune responses. J Immunol. 2013 Sep 1;191(5):2614-23.

    7) Chen S, Bohrer L, Rai A, Pan Y, Gan L, Zhou X, Bagchi A, Simon JA, Huang H*. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol 2010 Nov; 12(11):1108-14. (selected by Faculty of 1000)

    Huilin Huang
    Title Professor
    Professor Huilin Huang is interested in the basic and translational research of RNA epigenetics. She has published 28 peer-reviewed articles in top international journals, such as Nature, Cell, Cancer Cell, Nature Cell Biology and Cell Stem Cell. These studies have uncovered the mechanism and function of RNA m6A modification and noncoding RNAs in tumorigenesis and caner development, which have been cited for more than 4000 times. Prof. Huang is supported by several research grants from the National Natural Science Foundation of China and Natural Science Foundation of Guangdong Province.
    Research Interest(s)
    The research of Prof. Huang’s group is focused on (1) investigation of the function of RNA modification and its regulators during tumorigenesis and cancer development, and (2) discovery of small molecular inhibitors of RNA modification and development of effective therapeutic strategies. 
    2012 Ph.D., Biochemistry and Molecular Biology, Sun Yat-Sen University, Guangzhou, China
    2006 B.S., Bioengineering, Xi’an Jiaotong University, Xi’an, China

    2015-2017 Postdoc Fellow, College of Medicine, University of Cincinnati, Cincinnati, USA
    2013-2015 Postdoc Fellow, Northwestern University, Chicago, USA

    Professional experience
    2020-present Professor, Sun Yat-Sen University Cancer Center, Guangzhou, China
    2018-2020 Assistant Research Professor, Department of Systems Biology, City of Hope, Duarte, USA
    2017-2018 Staff Scientist, Department of Systems Biology, City of Hope, Duarte, USA

    Selected publications
    (1) Dong S, Wu Y, Liu Y, Weng H*, Huang H*. N6-methyladenosine Steers RNA Metabolism and Regulation in Cancer. Cancer Communications 2021, 41(7):538-559.

    (2) Huang H#, Weng H#, Chen J*. m6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell 2021, 37(3): 270-288.

    (3) Huang H#, Weng H#, Chen J*. The biogenesis and precise control of RNA m6A methylation. Trends in Genetics 2021, 36(1): 44-52.

    (4) Huang H#, Weng H#, Zhou K#, Wu T#, Zhao BS#, Sun M, Chen Z, Deng X, Xiao G, Auer F, Klemm L, Wu H, Zuo Z, Qin X, Dong Y, Zhou Y, Qin H, Tao S, Du J, Liu J, Lu Z, Yin H, Mesquita A, Yuan CL, Hu Y-C, Sun W, Su R, Dong L, Shen C, Li C, Qing Y, Jiang X, Wu X, Sun M, Guan J-L, Qu L, Wei M, Muschen M, Huang G*, He C*, Yang J*, and Chen J*. Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally. Nature 2019, 567:414-419. Highlighted by Nature Review Genetics (2019 20:254-255), Nature Chemical Biology (2019, 15:427), Cancer Research (2019, 79:2445-2446).

    (5) Huang H#, Weng H#, Sun W#, Qin X#, Shi H#, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL, Hu YC, Hüttelmaier S, Skibbe J, Su R, Dong L, Sun M, Li C, Nachtergaele S, Wang Y, Hu C, Ferchen K, Greis KD, Jiang X, Wei M, Qu L, Guan JL, He C*, Yang J*, Chen J*. Recognition of RNA N6-methyadenosine by IGF2BP proteins Enhances mRNA Stability. Nature Cell Biology 2018, 20:285-295. Featured by Nature Cell Biology with a News & Views article (2018; 20:230–232). 

    (6) Weng H#, Huang H#, Wu H#, Qin X#, Zhao BS#, Dong L#, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore LC, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy JC, Yang J, Qian Z, Wei M*, He C*, and Chen J*. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. Cell Stem Cell 2018, 22: 191-205. Highlighted by Cell Stem Cell with a Preview article (2018; 22:(139–141).

    (7) Huang H#, Zhang J#*, Harvey SE#, Hu X, Cheng C*. RNA G-quadruplex secondary structure promotes alternative splicing via the RNA-binding protein hnRNPF. Genes & Development. 2017, 31: 2296-2390.

    Updated November 2021
    Shijun Wen
    Title Associate Professor
    Dr. Shijun Wen is associate professor of medicinal chemistry in Experimental Research Department of Sun Yat-sen University. Dr. Wen obtained his Bachelor in chemistry from Jilin University, and PhD in organic chemistry in 2004 from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. During 2005-2010, He worked as a postdoctoral research fellow at Schools of Chemistry and Medicine, Southampton University, and then as a research associate at the Department of Chemistry, University of Cambridge. In November 2010, Dr. Wen joined Sun Yat-sen University Cancer Center as an associate professor working on the anticancer drug development and the synthetic methodology study. Dr. Wen has published more than 20 SCI research papers.
    Research Interest(s)

    Design and synthesis of anticancer agents to target abnormal metabolism and glycolysis of cancer cells and epigenetic enzymes. Development of synthetic methodologies to construct drug-like molecules for anticancer drug screening.


    1. 1995-1999: B.Sc. in chemistry, Department of Chemistry, Jilin University 

    2. 1999-2004: PhD. in organic chemistry, working on the total synthesis of cyclomarin C, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences.


    1.     Zhu D, Wu Y, Wu B, Luo B, Ganesan A, Pi R, WuF-H, Huang P, Wen S*. Three-component Pd/Cu-catalyzed cascade reactions ofcyclic iodoniums, alkynes, and boronic acids: an approach tomethylidenefluorenes. Organic Letters 2014, 16, 2350-2353 (IF 6.32)

    2.     Li M, Luo B, Liu Q, Hu Y, Ganesan A, Huang P, Wen S*. Synthesis of N-acyl-N,O-acetalsMediated by Titanium Ethoxide. Org. Lett. 2014, 16, 10-13. (IF 6.32)

    3.     Chen M, Liu Q, Liu A,Tan M, Xie Z, Uri A, Chen Z, Huang G, Sun Y, Ge H, Liu P, Li M, Li X, Wen S*, Pi R* Simply combiningfasudil and lipoic acid in a novel multitargeted chemical entity potentiallyuseful in central nervous system disorders. RSCAdvances, 2014, accepted. (IF 3.7)

    4.     Mageed SN, Cunningham F, Hung AW, SilvestreHL, Wen S, Blundell TL, AbellC, McConkey GA.Pantothenicacid biosynthesis in the parasite Toxoplasma gondii: a target for chemotherapy.  AntimicrobAgents Chemother. 2014 Jul21. pii: AAC.02640-14. [Epub ahead of print] (IF 4.45)

    5.     Chen M, Tan M, Jing M, Liu A, Liu Q, Wen S, Chen Z, Chao X, He X,Ramassamy C, Gao Y, Pi R. Berberine protects homocysteic acid-induced HT-22 celldeath: involvement of Akt pathway. MetabBrain Dis. 2014 Jul23. [Epub ahead of print] (IF 2.40)

    6.     Wang L, Wang R, Jin M, Huang Y, Liu A, Qin J,Chen M, Wen S, Pi R, Shen W. Carvedilol Attenuates6-Hydroxydopamine-Induced Cell Death in PC12 Cells: Involvement of Akt andNrf2/ARE Pathways. Neurochem Res. 2014 Jun 21. [Epubahead of print](IF 2.55)

    7.      Wen, S., Zhu, D.,Huang, P. Targeting Cancer CellMitochondria as a Therapeutic Approach, FutureMed. Chem., 2013, 5(1):53-67. (IF 4.0)

    8.      Zhu D, LiuQ, Luo B, Chen M, Pi R, Huang P, WenS*. Synthesis of Carbazoles via One-Pot Copper-Catalyzed Amine Insertion into CyclicDiphenyleneiodoniums as a Strategy to Generate a Drug-Like Chemical Library. Adv. Synth. Catal. 2013, 355, 2172-2178(IF 5.54)

    9.      Zhu D, Chen M, Li M, Luo B, Zhao Y, Huang P, XueF, Rapposelli A, Pi R, WenS*. Discovery of novel N-substituted carbazoles as neuroprotectiveagents with potent anti-oxidative activity. Eur.J. Med. Chem. 2013, 68, 81-88. (IF 3.50)

    10.   Guan R, Xu X, Chen M, Hu H, Ge H, Wen S*, Zhou S, Pi R. Advancesin the studies of roles of Rho/Rho-kinase in diseases and the development ofits inhibitors. Eur. J. Med. Chem. 2013, 70, 613-622. (IF 3.50)

    11.   Zhou B, Zuo Y, Li B, Wang H, Liu H, Wang X, Qiu X, Hu Y, WenS, Du J, Bu X. Deubiquitinase Inhibition of 19S RegulatoryParticles by 4-Arylidene Curcumin Analogue AC17 Causes NF-κB Inhibition and p53Reactivation in Human Lung Cancer Cells. Mol Cancer Ther. 2013, 12(8):1381-92.(IF 5.23)

    12.   Li X, Lu W, Hu Y, Wen S, Qian C, Wu W, Huang P*.Effective inhibition of nasopharyngeal carcinoma in vitro and in vivo bytargeting glycolysis with oxamate. Int. J. Oncol. 2013, 43(5): 1710-1718. (IF 2.40)

    13.    Abrahams GL, Kumar A, Savvi S, Hung AW, Wen S, Abell C, Barry CE 3rd,Sherman DR, Boshoff HI, Mizrahi V. Pathway-Selective Sensitization of Mycobacteriumtuberculosis for Target-Based Whole-Cell Screening. Chem Biol. 2012, 27, 19(7), 844-54. (IF 6.59)

    14.   Tiffon C., Adams J., van der Fits L., WenS, Townsend P., Ganesan A., Hodges E., Vermeer M., Packham G. Thehistone deacetylase inhibitors Vorinostat and Istodax downmodulate IL10expression in cutaneous T-cell lymphoma cells British Journal ofPharmacology, 2011, 162,1590-1602. (IF 4.99)

    15.   Hung A.W., Silvestre H.L., Wen S,Ciulli A., Blundell T.L., Abell C. Application of fragment growing and fragmentlinking to the discovery of novel inhibitors of Mycobacterium tuberculosispantothenate synthetase Angew. Chem. Int. Ed. 2009, 48, 8452-8456. (IF11.34)

    16.   Heikkila T.J., Surade S.,Silvestre H.L., Dias M.V.B., Ciulli A., Bromfield K., Scott D., Howard N., WenS, Wei A.H., Osborne D., Abell C. Blundell T.L. Fragment-based drugdiscovery in academia: experiences from a tuberculosis programme NATOSecurity through Science Series C: Environmental Security, 2009, 21-36.

    17.    Wen S, Packham, G.,Ganesan, A. Macrolactamization versus Macrolactonization: Total Synthesis ofFK228, the Depsipeptide Histone Deacetylase Inhibitor J Org Chem, 2008, 73, 9353-9361. (IF 4.64)

    18.    Wen S, Carey K., Nakao Y.,Fusetani N., Packham G., Ganesan A. Total Synthesis of Azumamide A andAzumamide E, Evaluation as Histone Deactylase Inhibitors, and Design of a MorePotent Analogue Organic Letters 2007,9 (6), 1105-1108. (IF6.32)

    19.   Yurek-George A., Cecil A., Mo A.H.K., WenS, Rogers H., Maeda S., Yoshida M., Packham G., Ganesan A., The FirstBiologically Active Synthetic Analogues of FK228, the Depsipeptide HistoneDeacetylase Inhibitor, J. Med. Chem., 2007; 50(23); 5720-5726. (IF5.48)

    20.    Wen, SJ, Hu, T.-S., Yao,Z.-J. Macrocylization Studies and Total Synthesis of Cyclomarin C, anAnti-inflammatory Marine Cyclopeptide, Tetrahedron, 2005, 61 (21), 4931-4938. (IF2.82)

    21.    Wen, SJ, Yao, Z.-J. TotalSynthesis of Cyclomarin C. Organic Letters 2004, 6 (16) 2721-2724. (IF6.32)

    22.    Wen, SJ, Zhang HY, Yao Z.-J. Synthesis of a fully protected (2S, 3R)-N-(1 ',1 '-dimethyl-2'-propenyl)-3-hydroxytrypto- phan from tryptophan. TetrahedronLett.2002, 43, 5291-5294. (IF2.39)


    Last updated on: August, 2014

    Yumin (Christie) Hu
    Title Associate Professor
    Dr. Yumin Hu received her M.D. degree from Guangzhou Medical College and obtained Ph.D. and postdoctoral training at The University of Texas, MD Anderson Cancer Center. She won the Rosalie B. Hite Fellowship for Cancer Research for year 2005-2008 for her Ph.D. research project “ROS Stress in Ras-Transformed Cancer Cells: Mechanisms and Therapeutic Implications”. In 2009, she won The Kimberly Patterson Fellowship Award for Leukemia Research for her postdoctoral fellow research projects “Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound -phenylethyl isothiocyanate”. In 2010, Dr. Yumin Hu was recruited to Sun Yat-sen University Cancer Center as Associate Professor and her research area has been focused on Metabolic alterations and redox regulation in cancer cells.
    Research Interest(s)

    Metabolic alterations and redox regulation in cancer cells

    Development of novel anticancer agents


    2002 Guangzhou Medical College, M. D. in Medical Sciences

    2008 The University of Texas Graduate School of Biomedical Sciences, MD Anderson Cancer Center,

    Ph.D. in Molecular Pathology/Cancer Biology


    1. Hu Y, Lu W, Chen G, Garcia-Manero G, and Huang P. K-rasG12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Research 2012 Feb;22(2):399-412

    2. Lu W, Hu Y (co-first-author), Chen G, Pelicano H, Chen Z, Zhang H, Huang P et al. “Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy” PLoS Biology  (2012);10(5):e1001326

    3. Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W,  Bhalla K, Keating M, Huang P, Garcia-Manero G,  “Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound -phenylethyl isothiocyanate” Blood (2010) 14;116(15):2732-41

    4. Hu Y, Rosen DG, Zhou Y, Feng L, Yang G, Liu J, Huang P, “Mitochondrial MnSOD Expression in Ovarian Cancer: Role in Cell Proliferation and Response to Oxidative Stress” The Journal of Biological Chemistry (2005) 280(47): 39485-92.

    5. Tang Z, Yuan S, Hu Y, Zhang H, Wu W, ZengZ, Yang J, Yun J, Xu R and Huang P. Over-Expression of GAPDH in Human Colorectal Carcinoma as a Preferred Target of 3-BrOP. Journal of Bioenergetics and Biomembranes  2012 Feb;44(1):117-25

    6. Li M, Luo B, Liu Q, Hu Y, Ganesan A, Huang P, Wen S. Synthesis of N-acyl-N,O-acetals Mediated by Titanium  Ethoxide. Org. Lett. 2014, 16, 10-13.

    7. Li X, Lu W, Hu Y, Wen S, Qian C, Wu W, Huang P. Effective inhibition of nasopharyngeal carcinoma in vitro and in vivo by targeting glycolysis with oxamate. Int J Oncol. 2013 Nov;43(5):1710-8.

    8. Liu PP, Liao J, Tang J, Wu WJ, Yang J, Zeng ZL, Hu Y, Wang P, Ju HQ, Xu RH, Huang P. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death & Differentiation, 2013 Oct 4 [Epub ahead of print].

    9. Wang P, Mai C, Wei YL, Zhao JJ, Hu Y, Zeng ZL, Yang J, Lu WH, Xu RH, Huang P. Decreased expression of the mitochondrial metabolic enzyme aconitase (ACO2) is associated with poor prognosis in gastric cancer. Med Oncol. 2013 Jun;30(2):552.

    10. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, and Hagop M Kantarjian. A phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. Accepted for publication on Journal of Clinical Oncology (2012)

    11. Chen G, Chen Z, Hu Y, and Huang P. Inhibition of Mitochondrial Respiration and Rapid Depletion of Mitochondrial Glutathione by β-Phenethyl Isothiocyanate: Mechanisms for Anti-Leukemia Activity. Antioxid Redox Signal (2011) 15(12):2911-21

    12. Wang SA, Abruzzo LV, Hasserjian RP, Zhang L, Hu Y, Zhang Y, Zhao M, Galili N, Raza A, Medeiros LJ, et al. Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. Leuk Res (2011) 35,351-357

    13. Yang H, Fang Z, Wei Y, Hu Y, Calin GA, Kantarjian HM., and Garcia-Manero G. Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. Am J Hematol (2011)86, 237-238.

    14. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Tambaro FP, Viallet J, O'Brien S, and Garcia-Manero, G. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res (2010)16, 3923-3932.

    15. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Viallet J, O'Brien S, and Garcia-Manero G. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy (2010)6, 976-978.

    16. Pelicano H, Lu W, Zhou Y, Zhang W, Chen Z, Hu Y, Huang P, “Mitochondrial   dysfunction and ROS imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism” Cancer Research (2009) 15;69(6):2375-83.

    17. Alexandre J, Hu Y, Lu W, Pelicano H, Huang P, “Novel Action of Paclitaxel against Cancer Cells: Bystander Effect Mediated by Reactive Oxygen Species” Cancer Research (2007) 67(8): 3512-3517

    18. Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, Zhang W, Plunkett W, Huang P, “Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism” The Journal of Cell Biology (2006) 175(6): 913-923.

    Last updated on: 2012

    Jia-Xing Yue
    Title Associate Professor
    Dr. Jia-Xing Yue is an associate professor of evolutionary genomics in Sun Yat-sen University Cancer Center (SYSUCC). Dr. Yue obtained his Bachelor degree in biological science at Nanjing University in 2007. He stay at Nanjing University to study molecular evolution of plant disease resistance genes for his graduate study and obtained Master degree in botany in 2010. Afterwards, he went abroad to study evolutionary genomics at Rice University (USA)  and obtained PhD degree in 2015. During this time, he also visited University of California, Berkeley (USA) and Institute for Research on Cancer and Aging, Nice (France) respectively as a visiting student scholar. After graduating from Rice University, he continued his academic training at and Institute for Research on Cancer and Aging, Nice (France) as a postdoc research fellow with a 3-year fellowship from Fondation ARC pour la Recherche sur le Cancer. Dr. Yue joined SYSUCC to establish his research group with the support from the 100 Top Talents Program of Sun Yat-sen University and the Pearl River Talent Recruitment Program of Guangdong Province in 2019. At SYSUCC, Dr. Yue is setting up a multi-disciplinary research platform that combines evolutionary biology, genomics, and bioinformatics, with a focus on genome architecture evolution and its functional impacts.
    Research Interest(s)

    Genomes are organized in a non-random way with strong architecture at different genomic scales (e.g. local genomic regions, subchromosomal domains, and whole chromosomes). A multi-scale understanding of such genome architecture is critical to dissect how genome functions and evolves. Therefore, the core mission of our lab is to investigate the evolutionary dynamics of genome architecture and its functional implications, especially in the context of cancer biology. Specifically, we want to understand how different scales of genome architecture variation (e.g. polyploidy, aneuploidy, subtelomere, structural variation, repetitive elements, etc.) may contribute to evolutionary adaptation and genome instability. To achieve this goal, we combine both in silico genomic analysis and experimental evolution approaches in our projects. On one hand, we can directly introduce various genome architecture variation to the cell and to monitor evolution in action through experimental variation; on the other hand, we can also dig into the genomic data generated by both basic and clinical research to retrospectively reconstruct the tempo and mode of genome architecture evolution.



    2003.09-2007.06    B. Sc. in Biological Science, School of Life Sciences, Nanjing University.

    2007.09-2010.06    M. Sc. in Botany, School of Life Sciences, Nanjing University.

    2010.08-2015.05    Ph. D. in Evolutionary Biology, BioSciences at Rice, Rice University.

    2013.08-2014.05    Visiting student researcher, Department of Molecular and Cell Biology, UC Berkeley.

    2014.08-2015.03    Visiting student, Institute for Research on Cancer and Aging, Nice (IRCAN), CNRS.

    2015.06-2019.10    Postdoctoral fellow, Institute for Research on Cancer and Aging, Nice (IRCAN), CNRS.


    corresponding author; ^ co-first author.

    1. Oleg Simakov^, Ferdinand Marlétaz^, Jia-Xing Yue, Brendan O’Connell, Jerry Jenkins, Alexander Brandt, Robert Calef, Che-Huang Tung, Tzu-Kai Huang, Jeremy Schmutz, Nori Satoh, Jr-Kai Yu, Nicholas H. Putnam, Richard E. Green, Daniel S. Rokhsar. (2020) Deeply conserved synteny resolves early events in vertebrate evolution. Nature Ecology and Evolution, (doi: 10.1038/s41559-020-1156-z) 

    2. Benjamin P Barré, Johan Hallin, Jia-Xing Yue, Karl Persson, Ekaterina Mikhalev, Agurtzane Irizar, Dawn Thompson, Mikael Molin, Jonas Warringer, Gianni Liti*. (2020) Intragenic repeat expansions control yeast chronological aging. Genome Research, (doi: 10.1101/gr.253351.119)

    3. Liudmyla Lototska, Jia-Xing Yue, Jing Li, Marie-Josèphe Giraud-Panis, Zhou Songyang, Nicola J Royle, Gianni Liti, Jing Ye*, Eric Gilson*, Aaron Mendez-Bermudez*. (2020) Human RAP1 specifically protects telomeres of senescent cells from DNA damage. EMBO Reports, e49076. (doi: 10.15252/embr.201949076)

    4. Jia-Xing Yue*, Gianni Liti*. (2019) simuG: a general-purpose genome simulator. Bioinformatics, 35(21):4442–4444. (doi:10.1093/bioinformatics/btz424; software available at 

    5. Jia-Xing Yue*, Gianni Liti*. (2018) Long-read sequencing data analysis for yeasts. Nature Protocols, 13(6):1213–1231. (doi:10.1038/nprot.2018.025; software available at 

    6. Jackson Peter^, Matteo De Chiara^, Anne Friedrich, Jia-Xing Yue, David Pflieger, Anders Bergström, Anastasie Sigwalt, Benjamin Barré, Kelle Freel, Agnès Llored, Corinne Cruaud, Karine Labadie, Jean Marc Aury, Benjamin Istace, Kevin Lebrigand, Pascal Barbry, Stefan Engelen, Arnaud Lemainque, Gianni Liti*, Joseph Schacherer*. (2018) Genome evolution across 1,011 Saccharomyces cerevisiae isolates. Nature, 556(7701):339–344. (doi:10.1038/s41586-018-0030-5) 

    7. Jia-Xing Yue, Jing Li, Louise Aigrain, Johan Hallin, Karl Persson, Karen Oliver, Anders Bergström, Paul Coupland, Jonas Warringer, Marco Cosentino Lagomarsino, Gilles Fischer, Richard Durbin, Gianni Liti*. (2017) Contrasting genome dynamics between domesticated and wild yeasts. Nature Genetics, 49(6):913-924. (doi:10.1038/ng.3847) 

    8. Chun-Min Shan^, Jiyong Wang^, Ke Xu^, Huijie Chen, Jia-Xing Yue, Stuart Andrews, James J. Moresco, John R. Yates III, Peter L. Nagy, Liang Tong*, Songtao Jia*.  (2016) A histone H3K9M mutation traps histone methyltransferase Clr4 to prevent heterochromatin spreading. eLife, 5:e17903. (doi:10.7554/eLife.17903) 

    9. Jia-Xing Yue, Iryna Kozmikova, Hiroki Ono, Carlos W. Nossa, Zbynek Kozmik, Nicholas H. Putnam, Jr-Kai Yu, Linda Z. Holland*. (2016) Conserved noncoding elements in the most distant genera of cephalochordates: the Goldilocks principle. Genome Biology and Evolution, 8(8):2387-2405. (doi:10.1093/gbe/evw158) 

    10. Jia-Xing Yue, Jr-Kai Yu, Nicholas H. Putnam, Linda Z. Holland*. (2014) The transcriptome of an amphioxus, Asymmetron lucayanum, from the Bahamas: a window into chordate evolution. Genome Biology and Evolution, 6(10):2681-2696. (doi:10.1093/gbe/evu212) 

    11. Jia-Xing Yue, Blake C. Meyers, Jian-Qun Chen, Dacheng Tian*, Sihai Yang*. (2012) Tracing the origin and evolutionary history of plant NBS-LRR genes. New Phytologist, 193(4):1049–1063. (doi:10.1111/j.1469-8137.2011.04006.x) 

    12. Jia-Xing Yue, Jinpeng Li, Dan Wang, Hitoshi Araki, Dacheng Tian, Sihai Yang*. (2010) Genome-wide investigation reveals high evolutionary rates in annual model plants. BMC Plant Biology, 10:242. (doi:10.1186/1471-2229-10-242) 

    Updated by International Office, Sun Yat-sen University Cancer Center

    Shi-Juan Mai
    Title Associate Professor

    Dr. Shi-Juan Mai is an associate professor of Oncology in the Experimental Research Department of Sun Yat-sen University Cancer Center (SYSUCC). She obtained her Ph.D. degree at Sun Yat-sen University and then was recruited by SYSUCC as research assistant in 2001. She received her postdoctoral training in the Laboratoire de Virologie Moléculaire of Université Lyon-1 in France from 2005 to 2006. Dr. Mai has gained 4 research grants from National Natural Science Foundation of China and published more than 30 SCI research papers.

    Research Interest(s)

    Study on the nonsense-mediated mRNA decay pathway in cancer.
    Study on the prognostic value and biological function of non-coding RNAs in cancer.


    1990-1995   Bachelor of Medicine, Henan medical university.

    1995-1998   Master of medicine in Pathology, Sun Yat-sen University.

    1998-2001   Doctor of medicine in Pathology, Sun Yat-sen University.

    2005-2006   Postdoctoral fellow in Virology, Université Lyon-1.


    1. Mai S, Xiao R, Shi L, Zhou X, Yang T, Zhang M, Weng N, Zhao X, Wang R, Liu J, Sun R, Qin H, Wang H. MicroRNA-18a promotes cancer progression through SMG1 suppression and mTOR pathway activation in nasopharyngeal carcinoma. Cell Death Dis. 2019 Oct 28;10(11):819.

    2. Wen W, Mai SJ, Lin HX, Zhang MY, Huang JL, Hua X, Lin C, Long ZQ, Lu ZJ, Sun XQ, Liu SL, Yang Q, Zhu Q, Wang HY, Guo L. Identification of two microRNA signatures in whole blood as novel biomarkers for diagnosis of nasopharyngeal carcinoma. J Transl Med. 2019 Jun 3;17(1):186.

    3. Xiao RW, Shi L, Yang T, Zhang MY, Wang HY, Mai SJ. Identification of RRAS gene related to nasopharyngeal carcinoma based on pathway and network-based analyses. Transl Cancer Res. 2019 Apr;8(2):664-675 

    4. Shi L, Xiao R, Wang M, Zhang M, Weng N, Zhao X, Zheng XFS, Wang H, Mai S. MicroRNA-342-3p suppresses proliferation and invasion of nasopharyngeal carcinoma cells by directly targeting Cdc42.Oncol Rep. 2018 Nov;40(5):2750-2757.

    5. Wang MH, Sun R, Zhou XM, Zhang MY, Lu JB, Yang Y, Zeng LS, Yang XZ, Shi L, Xiao RW, Wang HY, Mai SJ. Epithelial cell adhesion molecule overexpression regulates epithelial-mesenchymal transition, stemness and metastasis of nasopharyngeal carcinoma cells via the PTEN/AKT/mTOR pathway. Cell Death Dis. 2018 Jan 5;9(1):2.

    6. Wang MH, Zhou XM, Zhang MY, Shi L, Xiao RW, Zeng LS, Yang XZ, Zheng XFS, Wang HY, Mai SJ. BMP2 promotes proliferation and invasion of nasopharyngeal carcinoma cells via mTORC1 pathway. Aging (Albany NY). 2017 Apr;9(4):1326-1340.

    7. Zhang JX, Mai SJ, Huang XX, Wang FW, Liao YJ, Lin MC, Kung HF, Zeng YX, Xie D. MiR-29c mediates epithelial-to-mesenchymal transition in human colorectal carcinoma metastasis via PTP4A and GNA13 regulation of β-catenin signaling. Ann Oncol. 2014 Nov;25(11):2196-204.

    8. Zhang JX, Qian D, Wang FW, Liao DZ, Wei JH, Tong ZT, Fu J, Huang XX, Liao YJ, Deng HX, Zeng YX, Xie D, Mai SJ. MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy. Cancer Lett. 2013 Feb 1;329(1):91-8.

    9. Zhang JX, Huang XX, Cai MB, Tong ZT, Chen JW, Qian D, Liao YJ, Deng HX, Liao DZ, Huang MY, Zeng YX, Xie D, Mai SJ. Overexpression of the secretory small GTPase Rab27B in human breast cancer correlates closely with lymph node metastasis and predicts poor prognosis. J Transl Med. 2012 Dec 5;10:242.

    10. Wang FW, Wu XR, Liu WJ, Liao YJ, Lin S, Zong YS, Zeng MS, Zeng YX, Mai SJ, Xie D. Heat shock factor 1 upregulates transcription of Epstein-Barr Virus nuclear antigen 1 by binding to a heat shock element within the BamHI-Q promoter. Virology. 2011 Dec 20;421(2):184-91.

    Updated by International Office, Sun Yat-sen University Cancer Center

    Huai-Qiang Ju
    Title Associate Professor

    Prof. Huai-Qiang Ju is an Associate Professor of Department of Experiment Research. He was graduated from Sun Yat-sen University with Ph.D. degree in molecular medicine (2014), and recruited to Sun Yat-sen University Cancer Center as Associate Professor via the “One Hundred Talents Project of Sun Yat-sen University” (2017). Also, he was awarded as The Young Zhujiang Scholars from Ministry of Education of Guangdong (2018), and the Distinguished Young Scholar Professor of Guangdong province (2018). He mainly focus on investigation the mechanisms of tumor microenvironment remodeling in gastrointestinal cancer.

    Research Interest(s)

    Investigate the molecular mechanisms of tumor microenvironment remodeling in gastrointestinal cancer, and develop novel diagnostic and therapeutic strategies for GI cancer.


    2013/01-2014/12, Exchange student, MD Anderson Cancer Center, Houston, Texas; Advisor: Paul J. Chiao

    2011/09-2013/01, Ph.D. of Molecular Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China; Advisor: Prof. Peng Huang

    2008/09-2011/06, Master of Genetics, Jinan University, Guangzhou, China; Advisor: Prof. Yi-Fei Wang

    2004/09-2008/06, Bachelor of Bioscience, Qingdao Agriculture University, Qingdao, China


    1. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming, J. Liu#, Z.X. Liu#, Q.N. Wu#, Y.X. Lu, C.W. Wong, L. Miao, Y. Wang, Z. Wang, Y. Jin, M.M. He, C. Ren, D.S. Wang, D.L. Chen, H.Y. Pu, L. Feng, B. Li, D. Xie, M.S. Zeng, P. Huang, A. Lin, D. Lin, R.H. Xu, H.Q. Ju*, Nat Commun 11(1) (2020) 1507.

    2. Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers, Y. Wang#, J.H. Lu#, F. Wang#, Y.N. Wang, M.M. He, Q.N. Wu, Y.X. Lu, H.E. Yu, Z.H. Chen, Q. Zhao, J. Liu, Y.X. Chen, D.S. Wang, H. Sheng, Z.X. Liu, Z.L. Zeng, R.H. Xu, H.Q. Ju*, Cancer Lett 473 (2020) 74-89.

    3. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Y. Wang#, J.H. Lu#, Q.N Wu#, Y. Jing, D.S. Wang, Y.X Chen, J. Liu, X.J. Luo, Q. Meng, H.Y. Pu, Y.N. Wang, P.S. Hu, Z.X. Liu, Z.L. Zeng, Q. Zhao, R. Deng, X.F. Zhu, H.Q. Ju*, R.H. Xu*, Mol Cancer 18(1) (2019), 174

    4. A circRNA signature predicts postoperative recurrence in stage II/III colon cancer, H.Q. Ju#, Q. Zhao#, F. Wang#, P. Lan, Z. Wang, Z.X. Zuo, Q.N. Wu, X.J. Fan, H.Y. Mo, L. Chen, T. Li, C. Ren, X.B. Wan, G. Chen, Y.H. Li, W.H. Jia, R.H. Xu*, EMBO Mol Med (2019) e10168.

    5. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma, T. Li#, P.S. Hu#, Z. Zuo#, J.F. Lin, X. Li, Q.N. Wu, Z.H. Chen, Z.L. Zeng, F. Wang, J. Zheng, D. Chen, B. Li, T.B. Kang, D. Xie, D. Lin, H.Q. Ju*, R.H. Xu*, Mol Cancer 18(1) (2019) 112.

    6. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications, H.Q. Ju#, Y.X. Lu#, D.L. Chen#, Z.X. Zuo, Z.X. Liu, Q.N. Wu, H.Y. Mo, Z.X. Wang, D.S. Wang, H.Y. Pu, Z.L. Zeng, B. Li, D. Xie, P. Huang, M.C. Hung, P.J. Chiao, R.H. Xu*,J Natl Cancer Inst 111(6) (2019). 584-597

    7. LncRNA CamK-A Regulates Ca(2+)-Signaling-Mediated Tumor Microenvironment Remodeling, L.J. Sang#, H.Q. Ju#, G.P. Liu, T. Tian, G.L. Ma, Y.X. Lu, Z.X. Liu, R.L. Pan, R.H. Li, H.L. Piao, J.R. Marks, L.J. Yang, Q. Yan, W. Wang, J. Shao, Y. Zhou, T. Zhou, A. Lin*, Mol Cell 72(1) (2018,Cover Article) 71-83 e7.

    8. Nicotinamide nucleotide transhydrogenase-mediated redox homeostasis promotes tumor growth and metastasis in gastric cancer, S. Li#, Z. Zhuang#, T. Wu#, J.C. Lin, Z.X. Liu, L.F. Zhou, T. Dai, L. Lu, H.Q. Ju*, Redox Biol 18 (2018) 246-255.

    9. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma, H.Q. Ju, H. Ying, T. Tian, J. Ling, J. Fu, Y. Lu, M. Wu, L. Yang, A. Achreja, G. Chen, Z. Zhuang, H. Wang, D. Nagrath, J. Yao, M.C. Hung, R.A. DePinho, P. Huang, R.H. Xu, P.J. Chiao*, Nat Commun 8 (2017) 14437.

    10. ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition, H.Q. Ju#, G. Zhan#, A. Huang, Y. Sun, S. Wen, J. Yang, W.H. Lu, R.H. Xu, J. Li, Y. Li, G. Garcia-Manero, P. Huang, Y. Hu*, Leukemia 31(10) (2017) 2143-2150.

    Updated by International Office, Sun Yat-sen University Cancer Center

    Jing Li
    Title Associate Professor

    Dr. Jing Li joined Sun Yat-sen University Cancer Center (SYSUCC) in November 2019. Currently, she is an associate professor at the department of experimental research with the support of “the 100 Top Talents Program” of Sun Yat-sen University. Dr. Li obtained her Bachelor degree in biological science at Nanjing University in 2009. She continued her PhD training in Nanjing University under the advisement of Dr. Dacheng Tian and got her PhD degree in 2014. During that time, she applied both wet lab and bioinformatics approaches to understand the basic questions in genetics and molecular evolution, including the evolution of plant resistant genes and the influence of GC-content on amino acid usages. After that, she moved to Nice (France) to continue the training as postdoc with the fellowship from Fondation ARC pour la Recherche sur le Cancer. During her postdoc from 2014 to 2019, she worked with Dr. Gianni Liti at Centre National de la Recherche Scientifique (CNRS), Institute for Research on Cancer and Aging, Nice (IRCAN) and tried to understand the mechanisms of how cells getting adapted to drugs, briefly, how drug resistance occurring  and evolving by pre-existing genetic variation and de novo mutations. At SYSUCC, Dr. Li is setting up multiple experimental systems and bioinformatics pipelines to understand evolutionary dynamics of cancer development and the underlying mechanisms of drug persistence and resistance.

    Research Interest(s)

    Dr. Jing Li has broad interest in genetics, genomics and evolution, especially fascinated by the open question “how organisms respond to the changing environments by adaptive evolution”. The use of drugs is one of the most important approaches to treat cancer. However, “smart” cancer cells respond to the changing environments and evolve to search for various ways to escape the drug treatment, resulting in drug resistance. In order to overcome drug resistance, it is of great significance to understand the dynamics of how resistance arises. By experimental evolution and high-throughput approaches, we are able to track and investigate the detailed changes (e.g. genomic alterations, epigenetic modifications, transcriptome regulation) of cancer cells during adaptive evolution. On the other hand, once the cancer cells acquire drug resistance, they must have fitness costs (evolutionary trap). By high-throughput functional screen and phenotyping, we are able to identify such costs, which provide the potential targets to overcome resistance.


    Postdoctoral fellow, Centre National de la Recherche Scientifique (CNRS), Institute for Research on Cancer and Aging, Nice (IRCAN), France. Advised by Dr. Gianni Liti.

    Ph.D. in Biology, School of Life Sciences, Nanjing University, China. Advised by Dr. Dacheng Tian.

    B.Sc. in Biological Science, School of Life Sciences, Nanjing University, China.


    Selected publications

    Shared Molecular Targets Confer Resistance over Short and Long Evolutionary Timescales. Li, J., Vázquez-García, I., Persson, K., González, A., Yue, J.-X., Barré, B., Hall, M.N., Long, A., Warringer, J., Mustonen, V., Liti, G.*. Mol. Biol. Evol. 36, 691–708, 2019.

    Identifying a large number of high-yield genes in rice by pedigree analysis, whole-genome sequencing, and CRISPR-Cas9 gene knockout. Huang, J.#, Li, J.#, Zhou, J., Wang, L., Yang, S., Hurst, L.D.*, Li, W.-H.*, Tian, D.*. Proc. Natl. Acad. Sci. U. S. A. 115, E7559–E7567, 2018

    Contrasting evolutionary genome dynamics between domesticated and wild yeasts. Yue, J.-X., Li, J., Aigrain, L., Hallin, J., Persson, K., Oliver, K., Bergström, A., Coupland, P., Warringer, J., Lagomarsino, M.C., Fischer, G., Durbin, R., Liti, G.*. Nat. Genet. 49, 913–924, 2017

    GC-Content of Synonymous Codons Profoundly Influences Amino Acid Usage. Li, J.#, Zhou, J.#*, Wu, Y., Yang, S., Tian, D.*. G3 Bethesda Md 5, 2027–2036, 2015

    Rapidly evolving R genes in diverse grass species confer resistance to rice blast disease. Yang, S.#, Li, J.#, Zhang, X.#, Zhang, Q., Huang, J., Chen, J.-Q., Hartl, D.L.*, Tian, D.*. Proc. Natl. Acad. Sci. U. S. A. 110, 18572–18577, 2013

    Unique evolutionary pattern of numbers of gramineous NBS–LRR genes. Li, J.#, Ding, J.#, Zhang, W., Zhang, Y., Tang, P., Chen, J.-Q., Tian, D.*, Yang, S.*. Mol. Genet. Genomics 283, 427–438, 2010

    Last updated: April 2020 by International Office, Sun Yat-sen University Cancer Center

    Qi Zhao
    Title Associate Professor

    Dr Qi Zhao is currently an associate professor of cancer genomics in Sun Yat-sen University Cancer Center (SYSUCC). He gained his Ph.D of Bioinformatics at Sun Yat-sen university in 2016.  Then he finished a 3-year Postdoc training in Oncology at Sun Yat-sen Cancer Center. During the period of postdoc training, Dr Zhao was one of the core members in bioinformatics center of the department and mainly charged with development and deployment of NGS pipeline in high performance computing clusters. He is also in charge of cancer microbiome research platform.  He joined Sun Yat-sen University Cancer Center as an Associate Professor in November 2019. He focus on GI cancer bioinformatics and mainly work on related bioinformatic tool development and biomarker discovery from multi-omic cancer dataset. He has published more than 50 peer-reviewed papers, including some papers in high impact journals such as JAMA oncology, Cell Research, Science Transl Med, Nature Communications, EMBO Mol Med. Nucleic Acid Res, Briefings in Bioinformatics. 

    Phone +86-020-87342609
    Research Interest(s)

    Development of novel algorithm, application, database tools for cancer omic data analysis; Identification of ICI biomarkers for tumor diagnosis and prognosis with machine-learning approaches: Dissecting genomic-clinical associations in GI cancers.

    Education 2005  B.S. in Bioengineering
    Shaanxi University of Science & Technology in Xi’an, Shaanxi, China
    2011 Ph.D. in Bioinformatics
    Sun Yat-sen University, Guangzhou, Guangdong, China
    2016-2019 Postdoc in Oncology
    Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

    1. Zhao Qi*, Wang Feng#,*, Chen Yan-Xing*, Chen Shifu*, Yao Yi-Chen, Zeng Zhao-Lei, Jiang Teng-Jia, Wang Ying-Nan, Wu Chen-Yi, Jing Ying, Huang You-Sheng, Zhang Jing, Wang Zi-Xian, He Ming-Ming, Pu Heng-Ying, Mai Zong-Jiong, Wu Qi-Nian, Long Renwen, Zhang Xiaoni, Huang Tanxiao, Xu Mingyan, Qiu Miao-Zheng, Luo Hui-Yan, Li Yu-Hong, Zhang Dong-Shen, Jia Wei-Hua, Chen Gong, Ding Pei-Rong, Li Li-Ren, Lu Zheng-Hai, Pan Zhi-Zhong, Xu Rui-Hua#. Comprehensive profiling of 1015 patients’ exomes reveals genomic-clinical associations in colorectal cancer. Nature Communications, 2022. 13(1) 1-17.

    2. Mengni Liu*, Jianyu Chen*, Xin Wang, Chengwei Wang, Xiaolong Zhang, Yubin Xie, Zhixiang Zuo, Jian Ren#, Qi Zhao#. MesKit: a tool kit for dissecting cancer evolution of multi-region tumor biopsies through somatic alterations. gigaScience. 2021 May 15;81(10):2636-2650.

    3. Qi-Nian Wu*, Xiao-Jing Luo*, Jia Liu*, Yun-Xin Lu, Yun Wang, Jingjing Qi, Ze-Xian Liu, Qi-Tao Huang, Ze-Kun Liu, Jia-Bin Lu, Ying Jin, Heng-Ying Pu, Pei-Shan Hu, Jia-Bo Zheng, Zhao-Lei Zeng, Huai-Qiang Ju, Dan Xie, Qi Zhao#, Ruihua Xu#. MYC-Activated LncRNA MNX1-AS1 Promotes the Progression of Colorectal Cancer by Stabilizing YB1. Cancer Research. 2021 May 15;81(10):2636-2650.  

    4. Teng-Jia Jiang*, Fang Wang*, Ying-Nan Wang*, Jia-Jia Hu, Pei-Rong Ding, Jun-Zhong Lin, Zhi-Zhong Pan, Gong Chen, Jian-Yong Shao, Rui-hua Xu, Qi Zhao#, Feng Wang#. Germline mutational profile of Chinese patients under 70 years old with colorectal cancer. Cancer Communications, 2020 Nov;40(11):620-632

    5. Huiyan Luo*, Qi Zhao*, Wei Wei*, Lianghong Zheng*, Shaohua Yi*, Gen Li, Wenqiu Wang, Hui Sheng, Hengying Pu, Haiyu Mo, Zhixiang Zuo, Zexian Liu, Chaofeng Li, Chuangbo Xie, Zhaolei Zeng, Weimin Li, Xiaoke Hao, Yuying Liu, Sumei Cao, Guoliang Xu, Wanli Liu, Sarah Gibson, Kang Zhang, Rui-Hua Xu#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction and screening of colorectal cancer. Science Translational Medicine. 01/2020, DOI:10.1126/scitranslmed.aax7533. 

    6. Huai-Qiang Ju*, Qi Zhao*, Feng Wang*, Ping Lan*, Zixian Wang*, Zhi-Xiang Zuo, Qi-Nian Wu, Xin-Juan Fan, Hai-Yu Mo, Li Chen, Xiang-Bo Wan, Gong Chen, Yu-Hong Li, Wei-Hua Jia, Rui-Hua Xu#. A circRNA signature predicts postoperative recurrence in stage II/III colon cancer. EMBO Molecular Medicine. 09/2019, 11(3), DOI:10.15252/emmm.201810168. 

    7. Qi Zhao*, Yu Sun*, Zekun Liu*, Hongwan Zhang, Xingyang Li, Kaiyu Zhu, Ze-Xian Liu#, Jian Ren#, Zhixiang Zuo#. CrossICC: Iterative consensus clustering of cross-platform gene expression data without adjusting batch effect. Briefings in Bioinformatics, 2019. DOI: 10.1093/bib/bbz116. 

    8. Qi Zhao*, Yu Sun*, Dawei Wang*, Hongwan Zhang, Kai Yu, Jian Zheng, Zhixiang Zuo: LncPipe: A Nextflow-based pipeline for identification and analysis of long non-coding RNAs from RNA-Seq data. Journal of Genetics and Genomics. 07/2018; 45(7). 

    9. Zhixiang Zuo*, Huanjing Hu*, Qingxian Xu*, Xiaotong Luo, Di Peng, Kaiyu Zhu, Qi Zhao#, Yubin Xie#, Jian Ren#. BBCancer: An expression atlas of blood-based biomarkers in the early diagnosis of cancers. Nucleic Acids Research. 10/2019, DOI:10.1093/nar/gkz942. 

    10. Feng Wang*, Qi Zhao*, Ying-Nan Wang, Ying Jin, Ming-Ming He, Ze-Xian Liu, Rui-Hua Xu*. POLE or POLD1 mutations are new predictive biomarkers for immunotherapy across multiple cancer types. JAMA oncology. 2019, DOI:10.1001/jamaoncol.2019.2963. 

    11. Qi Zhao*, Yubin Xie*, Yueyuan Zheng*, Shuai Jiang, Wenzhong Liu, Weiping Mu, Zexian Liu, Yong Zhao, Yu Xue, Jian Ren#: GPS-SUMO: A tool for the prediction of sumoylation sites and SUMO-interaction motifs. Nucleic Acids Research 05/2014; 42(W1). 

    Updated May 2022 by International Office, Sun Yat-sen University Cancer Center

    Guo-Kai Feng
    Title Associate Professor (Master's Supervisor)

    He focuses on tumor targeted molecular imaging and therapy and is interested in the transformation of scientific research. He screened and identified  several tumor-targeted peptides, nanobodies and antibodies (targeting to NRP-1, EDB-FN, KRas, Na+K+ ATPase α1 and BARF1), and translated them into tumor targeted imaging probes and therapeutic drugs.  His  leading transformation project named The Novel High Precision PET Probes Projecthas been completed. He also developed a pan-KRas degrader for treatment of KRas mutant cancers and helped crews to develop the EBV prophylactic and therapeutic mRNA vaccines against EBV associated disease.

    Research Interest(s)

    Tumor targeted molecular imaging and therapy.

    Education 2002-2007 College Degree in Medical Imaging
    Southern Medical University, Guangzhou, China

    2007-2010 M.M. in Pathophysiology
    Southern Medical University, Guangzhou, China

    2010-2013 Ph.D. in Oncology
    Sun Yat-Sen University, Guangzhou, China

    2013-2016 Postdoc in Oncology
    Sun Yat-Sen University, Guangzhou, China

    2016-2019 Assistant research fellow

    2019 to present Associate Professor

    1.First-in-human pilot study of an integrin α6-targeted radiotracer for SPECT imaging of breast cancer. Shi Gao#, Bing Jia#, Guokai Feng#, Chengyan Dong#, Hui Du, Lin Bai, Qian Zhong, Qingjie Ma*, Musheng Zeng*, Fan Wang*. Signal Transduction and Targeted Therapy (2020) 5:147. (IF: 39.3)
    2.Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. Cong Sun, Yin-Feng Kang1, Yuan-Tao Liu, Xiang-Wei Kong, Hui-Qin Xu, Dan Xiong, Chu Xie, Yi-Hao Liu, Sui Peng, Guo-Kai Feng*, Zheng Liu* and Mu-Sheng Zeng*. Signal Transduction and Targeted Therapy (2022) 7:42. (IF: 39.3)
    3.Rapid Development of SARS-CoV‑2 Spike Protein Receptor-Binding Domain Self Assembled Nanoparticle Vaccine Candidates. Yin-Feng Kang#, Cong Sun#, Zhen Zhuang#, Run-Yu Yuan#, Qing-Bing Zheng, Jiang-Ping Li, Ping-Ping Zhou, Xin-Chun Chen, Zhe Liu, Xiao Zhang, Xiao-Hui Yu, Xiang-Wei Kong, Qian-Ying Zhu, Qian Zhong, Miao Xu, Nan-Shan Zhong, Yi-Xin Zeng, Guo-Kai Feng*, Chang-Wen Ke*, Jin-Cun Zhao*, and Mu-Sheng Zeng*.  ACS Nano 2021, 15, 2738−2752. (IF:17.1)
    4.Integrin α6 targeted positron emission tomography imaging of hepatocellular carcinoma in mouse models. Guo-Kai Feng#, Jia-Cong Ye#, Wei-Guang Zhang#, Yan Mei, Chao Zhou, Yi-Tai Xiao, Xin-Ling Li, Wei Fan*, Fan Wang*, Mu-Sheng Zeng*. Journal of Controlled Release 310 (2019) 11–21. (IF:10.8)
    5.SPECT and Near-Infrared Fluorescence Imaging of Breast Cancer with a Neuropilin-1-Targeting Peptide. Guo-Kai Feng#, Rong-Bin Liu#, Meng-Qing Zhang#, Xiao-Xuan Ye, Qian Zhong, Yun-Fei Xia, Man-Zhi Li, Jun Wang, Er-Wei Song, Xing Zhang*, Zhao-Zhong Wu*, Mu-Sheng Zeng*. Journal of Controlled Release 192 (2014) 236–242. (IF:10.8)
    6.Identification of a sodium pump Na+/K+ ATPase α1-targeted peptide for PET imaging of breast cancer. Qian Wang#, Shi-Bing Li#, Yi-Ying Zhao#, Da-Nian Dai, Hui Du, Yan-Zhu Lin, Jia-Cong Ye, Jing Zhao, Wei Xiao, Yan Mei, Yi-Tai Xiao, Shi-Chu Liu, Yan Li, Yun-Fei Xia, Er-Wei Song, Gang-Hua Tang, Wei-Guang Zhang, Zhi-Jian Li, Xiao-Bin Zheng, De-Hai Cao, Man-Zhi Li, Qian Zhong, Zhong-Ping Chen, Chao-Nan Qian, Wei Fan*, Guo-Kai Feng*, Mu-Sheng Zeng*. Journal of Controlled Release 281 (2018) 178–188. (IF:10.8)
    7.An optimized integrin α6-targeted peptide for positron emission tomography/magnetic resonance imaging of pancreatic cancer and its precancerous lesion. Yan Mei#, Ying-He Li#, Xiao-Chun Yang#, Chao Zhou, Zhi-Jian Li, Xiao-Bin Zheng, Jia-Cong Ye, Cheng Li, Xuan-Hong Zhang, Jian-Min Yuan, Hui-Qiang Huang, Wei Fan, Wei-Guang Zhang*, Mu-Sheng Zeng*, Guo-Kai Feng*. Clinical and Translational Medicine. 2020;10:e157. (IF:10.6)
    8.EDB‑FN targeted probes for the surgical navigation, radionuclide imaging, and therapy of thyroid cancer. Ruping Li#, Huihui He#, Xinling Li#, Xiaobin Zheng#, Zhijian Li, Hu Zhang, Jiacong Ye, Weiguang Zhang, Chunjing Yu*, Guokai Feng*, Wei Fan*. European Journal of Nuclear Medicine and Molecular Imaging. 2023 Feb 18. (IF:9.1)

    Updated by International Office, Sun Yat-sen University Cancer Center

    Zhao-Lei Zeng
    Title Associate Professor

    Dr. Zhao-lei Zeng is an Associate Professor of the Department of Experiment Research. She obtained her M.D. degree at Sun Yat-sen University of Medical Sciences in 2000 and Ph.D. degree in Oncology at Sun Yat-sen University in 2009. She had been a visiting associate professor at MD Anderson Cancer Center from 2014 to 2015. She was awarded as Tip-top Scientific and Technical Innovative Youth Talents of Guangdong special support program in 2016.  Dr. Zeng has published more than 70 peer-reviewed papers, including some papers in renowned journals such as Hepatology, Clinical Cancer Research, and Oncogene.

    Research Interest(s)

    Dr. Zhao-lei Zeng is interested in the molecular mechanisms of individualized treatment for gastrointestinal (GI) cancer and the study of developing prognostic and predictive markers in patients with GI cancer.


    Ph.D. in Oncology, Sun Yat-Sen University, China, 2005-2009.

    Master Degree in Oncology, Sun Yat-Sen University, China, 2000-2003.

    M.D. Sun Yat-Sen University of Medical Sciences, China, 1995-2000.


    Selected publications

    1. Yang DD#, Chen ZH#, Yu K#, Lu JH, Wu QN, Wang Y, Ju HQ, Xu RH, Liu ZX, Zeng ZL*. METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway. Front Oncol. 2020 Feb 26;10:115.

    2. Yang DD, Chen ZH, Wang DS, Yu HE, Lu JH, Xu RH, Zeng ZL*. Prognostic value of the serum apolipoprotein B to apolipoprotein A-I ratio in metastatic colorectal cancer patients. J Cancer 2020 Jan 1;11(5):1063-1074.

    3. Lu JH#, Zuo ZX#, Wang W#, Zhao Q, Qiu MZ, Luo HY, Chen ZH, Mo HY, Wang F, Yang DD, Wang Y, Wei XL, Wu QN, Ju HQ, Xu RH, Zeng ZL*. A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients. Cell Death Discov. 2018 Dec 18;4:116.

    4. Wang YN#, Zeng ZL#, Lu J#, Wang Y, Liu ZX, He MM, Zhao Q, Wang ZX, Li T, Lu YX, Wu QN, Yu K, Wang F, Pu HY, Li B, Jia WH, Shi M, Xie D, Kang TB, Huang P, Ju HQ, Xu RH. CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis. Oncogene. 2018 Nov;37(46):6025-6040.

    5. Chen DL#, Wang ZQ#, Zeng ZL#, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH, Xu RH. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology. 2014 Aug; 60(2):598-609.

    6. Zeng ZL#, Luo HY#, Yang J#, Wu WJ, Chen DL, Huang P, Xu RH. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clin Cancer Res. 2014 Feb 15;20(4):1042-52.

    7. Chen DL#, Zeng ZL#, Yang J#, Ren C, Wang DS, Wu WJ, Xu RH. L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer. J Hematol Oncol. 2013 Jun 27;6:43.

    8. Wu WJ#, Zhang Y#, Zeng ZL#, Li XB, Hu KS, Luo HY, Yang J, Huang P, Xu RH. Beta-phenylethyl isothiocyanate reverses platinum resistance by a GSH-dependent mechanism in cancer cells with epithelial-mesenchymal transition phenotype. Biochem Pharmacol. 2013 Feb 15;85(4):486-96.

    9. Zeng ZL#, Wu WJ#, Yang J#, Tang ZJ, Chen DL, Qiu MZ, Luo HY, Wang ZQ, Jin Y, Wang DS, Xu RH. Prognostic relevance of melanoma antigen D1 expression in colorectal carcinoma. J Transl Med. 2012 Aug 31;10:181.

    10. Zeng Z#, Lin H#, Zhao X#, Liu G, Wang X, Xu R, Chen K, Li J, Song L. Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Clin Cancer Res. 2012 Aug 1;18(15):4059-69.

    Updated May 2020 by International Office, Sun Yat-sen University Cancer Center

    Chuyong Lin
    Title Associate Professor

    Dr. Lin is an associate professor, doing research on breast cancer metastasis in prof. Libing Song’s lab at Sun Yat-sen University Cancer Center. He has published 16 papers as first or corresponding authors in renowned journals such as  EMBO Mol Med., Nature Commu., JCI, Cell Res., GUT, Cancer Res., and Clinical Cancer Res., and have been in charge of several national / provincial funded projects. His research paradigm uses a combined approach of molecular biology, cell biology, cancer animal models, and clinical samples to understand the underlying pathological and molecular basis of breast cancer metastasis, for the identification of potential treatment targets.

    Research Interest(s)

    1. Mechanism for metastatic colonization: Distant colonization represents the limiting step for the rate and speed of cancer metastasis. We use the triple negative breast cancer as the typical model to study how disseminated tumor cells survive, adapt to the unfamiliar distant microenvironment, and escape from dormancy to initiate distant metastases, thus resulting in much more frequent and earlier metastasis. We also explore potential strategies such as CRISPR for the targeting of key regulators.

    2. Mechanism for stress adaptation in cancer metastasis: Disseminated cells frequently encounter diverse biological stresses including anti-proliferative cytokines, hypoxia, starvation, immune attack, as well as the stress come from chemodrugs. We are interested in studying the alterations of protein post-translation modifications under harsh stress, which leads to the stress adaptation during metastasis and therapy.


    2008 – 2013
    Ph.D., Biochemistry and molecular biology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.

    2004 – 2008
    B.S., Biochemistry, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.


    1. Ye L#, Lin C#, Wang X#, Li Q#, Li Y, Wang M, Zhao Z, Wu X, Shi D, Xiao Y, Ren L, Jian Y, Yang M, Ou R, Deng G, Ouyang Y, Chen X, Li J, Song L. Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer. EMBO Mol Med. 2019 Dec;11(12):e10638.

    2. Liu J, Ye L, Li Q, Wu X, Wang B, Ouyang Y, Yuan Z, Li J, Lin C*. Synaptopodin-2 suppresses metastasis of triple-negative breast cancer via inhibition of YAP/TAZ activity. J Pathol. 2018 Jan;244(1):71-83.

    3. Lin C#, Liao W, Jian Y, Peng Y, Zhang X, Ye L, Cui Y, Wang B, Wu X, Xiong Z, Wu S, Li J, Wang X, Song L. CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling. Oncogene. 2017 Jun 29;36(26):3695-3705.

    4. Liu L#, Lin C#, Liang W#, Wu S, Liu A, Wu J, Zhang X, Ren P, Li M, Song L. TBL1XR1 promotes lymphangiogenesis and lymphatic metastasis in esophageal squamous cell carcinoma. Gut. 2015 Jan; 64(1):26-36.

    5. Lin C#, Song L#, Liu A#, Gong H, Lin X, Wu J, Li M, Li J.Overexpression of AKIP1 Promotes Angiogenesis and Lymphangiogenesis in Human Esophageal Squamous Cell Carcinoma. Oncogene. 2015 Jan 15;34(3):384-93.

    6. Lin C#, Liu A#, Zhu J, Zhang X, Wu G, Ren P, Wu J, Li M, Li J, Song L.miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma. Nat Commun. 2014 Aug 6;5:4620.

    7. Song L#, Lin C#, Gong H, Wang C, Liu L, Wu J, Tao S, Hu B, Cheng S, Li M, Li J. miR-486 sustains NF-κB activity by disrupting multiple NF-κB-negative feedback loops. Cell Research. 2013 Feb; 23(2):274-89.

    8. Lin C#, Song L#, Gong H, Liu A, Lin X, Wu J, Li M, Li J. Nkx2-8 Downregulation Promotes Angiogenesis and Activates NF-κB in Esophageal Cancer. Cancer Res. 2013 Jun 15; 73(12):3638-48.

    9. Jiang L#, Lin C#, Song L#, Wu J, Chen B, Ying Z, Fang L, Yan X, He M, Li J, Li M.MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-κB/IκBα negative feedback loop. J Clin Invest. 2012 Jan;122(1):33-47.

    10. Lin C#, Wu Z, Lin X, Yu C, Shi T, Zeng Y, Wang X, Li J, Song L. Knockdown of FLOT1 Impairs Cell Proliferation and Tumorigenicity in Breast Cancer through Upregulation of FOXO3a. Clin Cancer Res. 2011 May 15;17(10):3089-99.

    Updated May 2020 by International Office, Sun Yat-sen University Cancer Center

    Yuchen Cai
    Title Associate Professor

    Dr. Yu-chen Cai is an associate professor of oncology in the Experiment Research Department of Sun Yat-sen University Cancer Center (SYSUCC). She obtained her Ph.D. degree in oncology at Sun Yat-sen University in 2009. She has been a research assistant at Li Ka Shing Faculty of Medicine of the University of Hong Kong from 2012 to 2014. She has been a visiting associate professor at Karolinska Institutet from 2018 to 2019.  Dr Cai has published more than 30 peer-reviewed papers.

    Research Interest(s)

    Biology and mechanism of the proliferation and metastasis in triple-negative breast cancer.


    Ph.D. in Oncology, Sun Yat-sen University

    Master Degree in Oncology, Sun Yat-sen University

    Bachelor Degree in Biology, Sun Yat-sen University


    1. Yu-Chen Cai#, Hang Yang#, Ke-Feng Wang, Tan-Huan Chen, Wen-Qi Jiang*, Yan-Xia Shi*. ANGPTL4 overexpression inhibits tumor cell adhesion and migration and predicts favorable prognosis of triple-negative breast cancer. BMC Cancer. 2020 Sep 14;20(1):878

    2. Yang L#, Cai Y#, Zhang D, Sun J, Xu C, Zhao W, Jiang W*, Pan C*. miR-195/miR-497 Regulate CD274 Expression of Immune Regulatory Ligands in Triple-Negative Breast Cancer. J Breast Cancer. 2018 Dec;21(4):371-381

    3. Wang D*, Lee MMS, Shan G, Kwok RTK, Lam JWY, Su H*, Cai Y*, Tang BZ*. Highly Efficient Photosensitizers with Far-Red/Near-Infrared Aggregation-Induced Emission for In Vitro and In Vivo Cancer Theranostics. Adv Mater. 2018 Sep;30(39): e1802105

    4. Fengshou Wu#, Huifang Su#, Yuchen Cai#, Wai-Kwok Wong, Wenqi Jiang*, Xunjin Zhu*. Porphyrin-Implanted Carbon Nanodots for Photoacoustic Imaging and in Vivo Breast Cancer Ablation. ACS Applied Bio Materials. 2018, 1: 110-117

    5. Yang H#, Cai YC#, Cao Y, Song M, An X, Xia Y, Wei J, Jiang WQ, Shi YX*. The prognostic value of Tiam1 protein expression in head and neck squamous cell carcinoma: a retrospective study. Cancer Communication. 2015, 34: 51.

    6. Xia Q#, Cai YC#, Peng R,Wu G, Shi Y*, Jiang W*. The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition. Int J Oncol. 2014 Mar;44(3): 735-744

    7. Cai YC#, Xia Q#, Su QG, Luo RZ, Sun YL, Shi YX*, Jiang WQ*. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death in human nasopharyngeal carcinoma cells. Int J Mol Med. 2013 Apr; 31(4): 904-912.

    8. Cai YC, Zou Y, Ye YL, Sun HY, Su QG, Wang ZX, Zeng ZL, Xian LJ*. Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium(M410). Invest New Drugs. 2011 Apr; 29(2): 300-311.

    9. Wang KF#, Yang H#, Jiang WQ, Li S*, Cai YC*. Puquitinib mesylate (XC-302) induces autophagy via the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells. Int J Mol Med. 2015, 36: 1556-1562

    Updated June 2022 by International Office, Sun Yat-sen University Cancer Center

    Ping Zhou
    Title Associate Professor
    Dr. Ping Zhou is an associate professor in Sun Yat-sen University Cancer Center (SYSUCC). He obtained his Ph.D. degree in Huazhong Agricultural University in 2011. From 2012 to 2020, he worked as a postdoc in Feng Shao’s lab at the National Institute of Biological Sciences (NIBS), Beijing, China. During his postdoctoral research, Dr. Zhou focused on bacterial infection and host innate immune response and discovered that intracellular alpha-kinase 1 (ALPK1) functions as a novel pattern recognition receptor which senses bacterial metabolite ADP-heptose leading to inflammatory response.
    Research Interest(s)
    The mechanism and transformation prospect of innate immune signaling pathway in pathogen infection and non-infectious diseases.
    2012.03-2020.08 Postdoctoral fellow, National Institute of Biological Sciences (NIBS), Beijing, China

    2008.09-2011.12 Ph.D. in Animal genetics, breeding and reproduction, Huazhong Agricultural University, Wuhan, China

    2005.09-2008.06 Master degree in Animal genetics, breeding and reproduction, Huazhong Agricultural University, Wuhan, China

    2001.09-2005.06 B.S. in Biotechnology, Huazhong Agricultural University, Wuhan, China
    1. A Bacterial Effector Reveals the V-ATPase-ATG16L1 Axis that Initiates Xenophagy. Yue Xu, Ping Zhou, Sen Cheng, Qiuhe Lu, Kathrin Nowak, Ann-Katrin Hopp, Lin Li, Xuyan Shi, Zhiwei Zhou, Wenqing Gao, Da Li, Huabin He, Xiaoyun Liu, Jingjin Ding, Michael O. Hottiger, Feng Shao*. Cell, 2019

    2. Alpha-kinase 1 is a cytosolic innate immune receptor for bacterial ADP-heptose. Ping Zhou#, Yang She#, Na Dong, Peng Li, Huabin He, Alessio Borio, Qingcui Wu, Shan Lu, Xiaojun Ding, Yong Cao, Yue Xu, Wenqing Gao, Mengqiu Dong, Jingjin Ding, Da-Cheng Wang, Alla Zamyatina, Feng Shao*. Nature, 2018 (#Equal contribution)

    3. N(epsilon)-fatty acylation of multiple membrane-associated proteins by Shigella IcsB effector to modulate host function. Wang Liu#, Yan Zhou#, Tao Peng#, Ping Zhou, Xiaojun Ding, Zilin Li, Haoyu Zhong, Yue Xu, She Chen, Howard C. Hang*, Feng Shao*. Nature Microbiology, 2018. (#Equal contribution)

    4. A hybridization-chain-reaction-based method for amplifying immunosignals. Rui Lin, Qiru Feng, Peng Li, Ping Zhou, Ruiyu Wang, Zhe Liu, Zhiqiang Wang, Xiangbing Qi, Nan Tang, Feng Shao, Minmin Luo*. Nature Methods, 2018.

    5. Ubiquitination and degradation of GBPs by a Shigella effector to suppress host defence. Peng Li, Wei Jiang, Qin Yu, Wang Liu, Ping Zhou, Jun Li, Junjie Xu, Bo Xu, Fengchao Wang, Feng Shao*. Nature, 2017.

    Updated March 2021 by International Office, Sun Yat-sen University Cancer Center

    Wenting Liao
    Title Associate Professor
    Dr. Wenting Liao is an associate professor in Sun Yat-sen University Cancer Center. She obtained her Ph.D. degree in Sun Yat-sen University Cancer Center in 2008. She finished her postdoctoral training in Department of Pathology, Southern Medical University of China in 2010. From 2015 to 2018, she worked as a visiting scientist in the DePinho Laboratory at MD Anderson Cancer Center, US. 
    Research Interest(s)
    Colorectal cancer (CRC) is a major cause of cancer mortality worldwide. Despite improvements in systemic treatments for patients with metastatic disease, the 5-year survival rate remains poor. Immune checkpoint blockade (ICB) therapy has provided durable clinical responses in multiple difficult-to-treat tumor types. However, ICB has shown no activity in almost 95% percent of metastatic CRC. Our research focuses on dissecting the molecular mechanisms of immune evasion and resistance to immune therapy in metastatic CRC and KRAS mutated cancers with the goal of illuminating effective therapeutic strategies.
    2015-2018 Visiting Scientist, MD Anderson Cancer Center.

    2010 Postdoc in Pathology, Southern Medical University, China.

    2008 Ph.D. in Oncology, Sun Yat-sen University Cancer Center, China.

    2005 M.S. in Oncology, Sun Yat-sen University Cancer Center, China.

    2002 B.S. in Clinical Medicine, HengYang Medical School, Hengyang, China.

    1. Huang C#,Ou R#, Chen X#, Zhang Y, Li J, Liang Y, Zhu X, Liu L, LiM, Lin D, Qiu J, Liu G, Zhang L, Wu Y, Tang H, Liu Y, Liang L, Ding Y*,LiaoW*. Tumor cell-derived SPON2 promotes M2-polarized tumor-associatedmacrophage infiltration and cancer progression by activating PYK2 in CRC.J Exp ClinCancer Res. 2021 Sep 28;40(1):304.

    2. Wang S#, Qiu J#, Liu L#, Su C, Qi L,Huang C, Chen X, Zhang Y, Ye Y, Ding Y, Liang L*,LiaoW*.CREB5 promotes invasiveness and metastasis in colorectal cancer bydirectly activating MET.J Exp Clin Cancer Res. 2020 Aug25;39(1):168.

    3. Zhu X#, Wang F#, Wu X, Li Z, Wang Z, Ren X, ZhouY, Song F, Liang Y, Zeng Z, Liao W, Ding Y,LiaoW*, Liang L*. FBX8 promotes metastatic dormancy of colorectal cancer inliver.Cell Death Dis. 2020 Aug14;11(8):622.

    4. Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring DJ, Chang Q, Zhang J, Maru DM, Maeda DY, Zebala JA, Kopetz S, Wang YA*, DePinho RA*. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell. 2019 Apr 15;35(4):559-572.

    5. Ye Y#, Jiao H#, Wang S#, Xiao Z, Zhang D, Qiu J, Zhang L, Zhao Y, LiT, Liang-L,Liao W*, Ding Y*. Hypermethylation of DMTN promotesthe metastasis of colorectal cancer cells by regulating the actin cytoskeletonthrough Rac1 signaling activation. J Exp Clin Cancer Res. 2018 Dec4;37(1):299.

    6.Jian Y#,Wang M#, Zhang Y, Ou R, Zhu Z, Ou Y, Chen X, Liang X, Ding Y*, SongL*, Xu X*,Liao W*. JadefamilyPHD finger 3 (JADE3) increases cancer stemcell-like properties and tumorigenicity in colon cancer. Cancer Lett.2018 Apr 13;428:1-11.

    7. Lin C#,LiaoW#,Jian Y#, Peng Y, Zhang X, Ye L,Cui Y, Wang B, Wu X, Xiong Z, Wu S, Li J, Wang X*, Song L*. CGI-99 promotesbreast cancer metastasis via autocrine interleukin-6 signaling. Oncogene. 2017 Jun 29;36(26):3695-3705.

    8. JiaoH#, Ye Y#,Yang R, Sun H, Wang S, Wang Y, Xiao Z, He L, Cai J, Wei W, Chen Y, Gu C, Cai Y,Hu Y, Lai Q, Qiu J, Liang , Cao G, Liao WT*, Ding Y*.Down-regulation of SAFB sustains the NF-kappaB pathway by targeting TAK1 duringthe progression of colorectal cancer. ClinCancer Res. 2017 Sep 14;32(22):7108

    Updated November 2021 by International Office, Sun Yat-sen University Cancer Center

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.